11135616	19	Chinetti G	PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway.	Nature medicine	2001	166
19064999	19	Rader DJ	The role of reverse cholesterol transport in animals and humans and relationship to atherosclerosis.	Journal of lipid research	2009	136
19221221	19	McGillicuddy FC	Inflammation impairs reverse cholesterol transport in vivo.	Circulation	2009	114
20103563	19	Klaassen CD	Xenobiotic, bile acid, and cholesterol transporters: function and regulation.	Pharmacological reviews	2010	156
24385509	19	Westerterp M	ATP-binding cassette transporters, atherosclerosis, and inflammation.	Circulation research	2014	44
233137	174	Aden DP	Controlled synthesis of HBsAg in a differentiated human liver carcinoma-derived cell line.	Nature	1979	202
8594428	174	Mazzaferro V	Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis.	The New England journal of medicine	1996	790
9731568	174	-	A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators.	Hepatology	1998	231
10573521	174	Theise ND	The canals of Hering and hepatic stem cells in humans.	Hepatology	1999	113
11156649	174	Bolondi L	Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis.	Gut	2001	103
11391528	174	Yao FY	Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival.	Hepatology	2001	272
11394657	174	Trevisani F	Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status.	Journal of hepatology	2001	104
12029639	174	Hsu YS	Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B.	Hepatology	2002	100
12547409	174	Imamura H	Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy.	Journal of hepatology	2003	187
12851874	174	Capurro M	Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma.	Gastroenterology	2003	134
15042359	174	Zhang BH	Randomized controlled trial of screening for hepatocellular carcinoma.	Journal of cancer research and clinical oncology	2004	201
15665226	174	Lencioni R	Early-stage hepatocellular carcinoma in patients with cirrhosis: long-term results of percutaneous image-guided radiofrequency ablation.	Radiology	2005	112
15817682	174	Sato Y	Human mesenchymal stem cells xenografted directly to rat liver are differentiated into human hepatocytes without fusion.	Blood	2005	114
16137783	174	Marrero JA	GP73, a resident Golgi glycoprotein, is a novel serum marker for hepatocellular carcinoma.	Journal of hepatology	2005	87
16246200	174	Natsuizaka M	Clinical features of hepatocellular carcinoma with extrahepatic metastases.	Journal of gastroenterology and hepatology	2005	90
16542288	174	Colli A	Accuracy of ultrasonography, spiral CT, magnetic resonance, and alpha-fetoprotein in diagnosing hepatocellular carcinoma: a systematic review.	The American journal of gastroenterology	2006	66
16542289	174	Farinati F	Diagnostic and prognostic role of alpha-fetoprotein in hepatocellular carcinoma: both or neither?	The American journal of gastroenterology	2006	68
16778155	174	Terai S	Improved liver function in patients with liver cirrhosis after autologous bone marrow cell infusion therapy.	Stem cells	2006	94
16890600	174	Takayasu K	Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients.	Gastroenterology	2006	133
16945998	174	Herrera MB	Isolation and characterization of a stem cell population from adult human liver.	Stem cells	2006	92
17639088	174	di Bonzo LV	Human mesenchymal stem cells as a two-edged sword in hepatic regenerative medicine: engraftment and hepatocyte differentiation versus profibrogenic potential.	Gut	2008	61
18069697	174	Forner A	Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma.	Hepatology	2008	124
18182659	174	Chan HL	High viral load and hepatitis B virus subgenotype ce are associated with increased risk of hepatocellular carcinoma.	Journal of clinical oncology 	2008	58
18316609	174	Yamashita T	EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma.	Cancer research	2008	174
18350595	174	But DY	Natural history of hepatitis-related hepatocellular carcinoma.	World journal of gastroenterology	2008	66
18479363	174	Song W	Expression and clinical significance of the stem cell marker CD133 in hepatocellular carcinoma.	International journal of clinical practice	2008	53
18580463	174	Zheng SS	Liver transplantation for hepatocellular carcinoma: Hangzhou experiences.	Transplantation	2008	89
18972441	174	Zhang L	The stem cell niche of human livers: symmetry between development and regeneration.	Hepatology	2008	65
19064965	174	Chan SL	New utility of an old marker: serial alpha-fetoprotein measurement in predicting radiologic response and survival of patients with hepatocellular carcinoma undergoing systemic chemotherapy.	Journal of clinical oncology 	2009	56
19152426	174	Toso C	Reassessing selection criteria prior to liver transplantation for hepatocellular carcinoma utilizing the Scientific Registry of Transplant Recipients database.	Hepatology	2009	53
19223512	174	Goldman R	Detection of hepatocellular carcinoma using glycomic analysis.	Clinical cancer research 	2009	48
19302335	174	Nguyen VT	Hepatitis B-related hepatocellular carcinoma: epidemiological characteristics and disease burden.	Journal of viral hepatitis	2009	67
19362088	174	Marrero JA	Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma.	Gastroenterology	2009	97
19392863	174	Singal A	Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis.	Alimentary pharmacology and therapeutics	2009	113
19454616	174	Wang M	Novel fucosylated biomarkers for the early detection of hepatocellular carcinoma.	Cancer epidemiology, biomarkers and prevention 	2009	46
19731239	174	N'Kontchou G	Radiofrequency ablation of hepatocellular carcinoma: long-term results and prognostic factors in 235 Western patients with cirrhosis.	Hepatology	2009	55
19747749	174	Wu JC	Risk factors for early and late recurrence in hepatitis B-related hepatocellular carcinoma.	Journal of hepatology	2009	61
19766639	174	Salem R	Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes.	Gastroenterology	2010	158
19801927	174	Cherqui D	Liver resection for transplantable hepatocellular carcinoma: long-term survival and role of secondary liver transplantation.	Annals of surgery	2009	48
19805671	174	Riaz A	Alpha-fetoprotein response after locoregional therapy for hepatocellular carcinoma: oncologic marker of radiologic response, progression, and survival.	Journal of clinical oncology 	2009	51
19880964	174	Spee B	Characterisation of the liver progenitor cell niche in liver diseases: potential involvement of Wnt and Notch signalling.	Gut	2010	61
20057319	174	Sun HY	Gadoxetic acid-enhanced magnetic resonance imaging for differentiating small hepatocellular carcinomas (&amp;lt; or =2 cm in diameter) from arterial enhancing pseudolesions: special emphasis on hepatobiliary phase imaging.	Investigative radiology	2010	41
20066715	174	Carr BI	Therapeutic equivalence in survival for hepatic arterial chemoembolization and yttrium 90 microsphere treatments in unresectable hepatocellular carcinoma: a two-cohort study.	Cancer	2010	44
20209641	174	Pomfret EA	Report of a national conference on liver allocation in patients with hepatocellular carcinoma in the United States.	Liver transplantation 	2010	54
20339916	174	Malaguarnera G	Serum markers of hepatocellular carcinoma.	Digestive diseases and sciences	2010	49
20351325	174	Glazer ES	Phase II study of pegylated arginine deiminase for nonresectable and metastatic hepatocellular carcinoma.	Journal of clinical oncology 	2010	44
20578139	174	Davila JA	Use of surveillance for hepatocellular carcinoma among patients with cirrhosis in the United States.	Hepatology	2010	78
20683951	174	Asahina Y	Effect of aging on risk for hepatocellular carcinoma in chronic hepatitis C virus infection.	Hepatology	2010	40
20821352	174	Ghodsizadeh A	Generation of liver disease-specific induced pluripotent stem cells along with efficient differentiation to functional hepatocyte-like cells.	Stem cell reviews	2010	42
20876776	174	Mao Y	Golgi protein 73 (GOLPH2) is a valuable serum marker for hepatocellular carcinoma.	Gut	2010	52
21278583	174	Qu KZ	Circulating microRNAs as biomarkers for hepatocellular carcinoma.	Journal of clinical gastroenterology	2011	62
21294289	174	DuBay D	Liver transplantation for advanced hepatocellular carcinoma using poor tumor differentiation on biopsy as an exclusion criterion.	Annals of surgery	2011	45
21618574	174	Sangro B	Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation.	Hepatology	2011	109
21621346	174	Yoon SM	Radiotherapy plus transarterial chemoembolization for hepatocellular carcinoma invading the portal vein: long-term patient outcomes.	International journal of radiation oncology, biology, physics	2012	60
22374994	174	Singal AG	Effectiveness of hepatocellular carcinoma surveillance in patients with cirrhosis.	Cancer epidemiology, biomarkers and prevention 	2012	49
22414760	174	Personeni N	Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma.	Journal of hepatology	2012	39
22750200	174	Duvoux C	Liver transplantation for hepatocellular carcinoma: a model including α-fetoprotein improves the performance of Milan criteria.	Gastroenterology	2012	57
22846859	174	Bertino G	Hepatocellualar carcinoma serum markers.	Seminars in oncology	2012	37
23041304	174	Cescon M	Hepatocellular carcinoma locoregional therapies for patients in the waiting list. Impact on transplantability and recurrence rate.	Journal of hepatology	2013	26
23337478	174	Singal AG	Detection of hepatocellular carcinoma at advanced stages among patients in the HALT-C trial: where did surveillance fail?	The American journal of gastroenterology	2013	34
23564522	174	Asahina Y	α-fetoprotein levels after interferon therapy and risk of hepatocarcinogenesis in chronic hepatitis C.	Hepatology	2013	35
23874536	174	Zhong JH	Comparison of long-term survival of patients with BCLC stage B hepatocellular carcinoma after liver resection or transarterial chemoembolization.	PloS one	2013	43
24002931	174	Flecken T	Immunodominance and functional alterations of tumor-associated antigen-specific CD8+ T-cell responses in hepatocellular carcinoma.	Hepatology	2014	23
24096763	174	Zhong JH	Hepatic resection associated with good survival for selected patients with intermediate and advanced-stage hepatocellular carcinoma.	Annals of surgery	2014	69
24123097	174	Wong GL	On-treatment alpha-fetoprotein is a specific tumor marker for hepatocellular carcinoma in patients with chronic hepatitis B receiving entecavir.	Hepatology	2014	23
24462733	174	El-Serag HB	A new laboratory-based algorithm to predict development of hepatocellular carcinoma in patients with hepatitis C and cirrhosis.	Gastroenterology	2014	23
24649215	174	Zhao YJ	Tumor markers for hepatocellular carcinoma.	Molecular and clinical oncology	2013	32
24797281	174	Hameed B	Alpha-fetoprotein level &amp;gt; 1000 ng/mL as an exclusion criterion for liver transplantation in patients with hepatocellular carcinoma meeting the Milan criteria.	Liver transplantation 	2014	26
24836552	174	Takeda H	Clinical features associated with radiological response to sorafenib in unresectable hepatocellular carcinoma: a large multicenter study in Japan.	Liver international 	2015	17
24912628	174	Memeo R	Laparoscopic vs. open liver resection for hepatocellular carcinoma of cirrhotic liver: a case-control study.	World journal of surgery	2014	26
25271081	174	Hu B	Systemic immune-inflammation index predicts prognosis of patients after curative resection for hepatocellular carcinoma.	Clinical cancer research 	2014	29
25682869	174	Zhu M	Hepatitis B virus X protein induces expression of alpha-fetoprotein and activates PI3K/mTOR signaling pathway in liver cells.	Oncotarget	2015	19
25714016	174	Tang J	Circulation long non-coding RNAs act as biomarkers for predicting tumorigenesis and metastasis in hepatocellular carcinoma.	Oncotarget	2015	27
25804634	174	Xu X	Liver transplantation for hepatocellular carcinoma beyond the Milan criteria.	Gut	2016	17
25845839	174	Wen Y	Plasma miRNAs as early biomarkers for detecting hepatocellular carcinoma.	International journal of cancer	2015	20
26140083	174	Attwa MH	Guide for diagnosis and treatment of hepatocellular carcinoma.	World journal of hepatology	2015	22
26628466	174	Wahl DR	Outcomes After Stereotactic Body Radiotherapy or Radiofrequency Ablation for Hepatocellular Carcinoma.	Journal of clinical oncology 	2016	20
12171785	183	Brasier AR	Vascular inflammation and the renin-angiotensin system.	Arteriosclerosis, thrombosis, and vascular biology	2002	86
15592481	183	Heilbronn L	Failure of fat cell proliferation, mitochondrial function and fat oxidation results in ectopic fat storage, insulin resistance and type II diabetes mellitus.	International journal of obesity and related metabolic disorders 	2004	87
15690074	183	Bataller R	Liver fibrosis.	The Journal of clinical investigation	2005	894
25092601	183	Alge JL	Biomarkers of AKI: a review of mechanistic relevance and potential therapeutic implications.	Clinical journal of the American Society of Nephrology 	2015	23
16567827	197	Stefan N	Alpha2-Heremans-Schmid glycoprotein/fetuin-A is associated with insulin resistance and fat accumulation in the liver in humans.	Diabetes care	2006	88
18335040	197	Hennige AM	Fetuin-A induces cytokine expression and suppresses adiponectin production.	PloS one	2008	51
18612115	197	Ix JH	Fetuin-A and incident diabetes mellitus in older persons.	JAMA	2008	64
18633113	197	Stefan N	Plasma fetuin-A levels and the risk of type 2 diabetes.	Diabetes	2008	73
19029462	197	Weikert C	Plasma fetuin-a levels and the risk of myocardial infarction and ischemic stroke.	Circulation	2008	58
23337953	197	Stefan N	The role of hepatokines in metabolism.	Nature reviews. Endocrinology	2013	33
16186396	207	Plomgaard P	Tumor necrosis factor-alpha induces skeletal muscle insulin resistance in healthy human subjects via inhibition of Akt substrate 160 phosphorylation.	Diabetes	2005	91
17363567	207	Saxena NK	Concomitant activation of the JAK/STAT, PI3K/AKT, and ERK signaling is involved in leptin-mediated promotion of invasion and migration of hepatocellular carcinoma cells.	Cancer research	2007	106
17998146	207	Schmitz KJ	Activation of the ERK and AKT signalling pathway predicts poor prognosis in hepatocellular carcinoma and ERK activation in cancer tissue is associated with hepatitis C virus infection.	Journal of hepatology	2008	60
18649363	207	Li W	Diagnostic and prognostic implications of microRNAs in human hepatocellular carcinoma.	International journal of cancer	2008	86
19195051	207	Fabregat I	Dysregulation of apoptosis in hepatocellular carcinoma cells.	World journal of gastroenterology	2009	60
19208038	207	Chen JS	Involvement of PI3K/PTEN/AKT/mTOR pathway in invasion and metastasis in hepatocellular carcinoma: Association with MMP-9.	Hepatology research 	2009	62
19800084	207	Zhang H	Berberine lowers blood glucose in type 2 diabetes mellitus patients through increasing insulin receptor expression.	Metabolism	2010	49
19917848	207	Missiaglia E	Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathway.	Journal of clinical oncology 	2010	84
19996208	207	Davies MA	Integrated Molecular and Clinical Analysis of AKT Activation in Metastatic Melanoma.	Clinical cancer research 	2009	62
20299475	207	Houde VP	Chronic rapamycin treatment causes glucose intolerance and hyperlipidemia by upregulating hepatic gluconeogenesis and impairing lipid deposition in adipose tissue.	Diabetes	2010	107
20639898	207	Whittaker S	The role of signaling pathways in the development and treatment of hepatocellular carcinoma.	Oncogene	2010	190
20683952	207	Wang XQ	Octamer 4 (Oct4) mediates chemotherapeutic drug resistance in liver cancer cells through a potential Oct4-AKT-ATP-binding cassette G2 pathway.	Hepatology	2010	54
20830746	207	Wang N	Berberine induces autophagic cell death and mitochondrial apoptosis in liver cancer cells: the cellular mechanism.	Journal of cellular biochemistry	2010	48
21205925	207	Chen KF	Activation of phosphatidylinositol 3-kinase/Akt signaling pathway mediates acquired resistance to sorafenib in hepatocellular carcinoma cells.	The Journal of pharmacology and experimental therapeutics	2011	61
21475304	207	Vara D	Anti-tumoral action of cannabinoids on hepatocellular carcinoma: role of AMPK-dependent activation of autophagy.	Cell death and differentiation	2011	45
21538343	207	Zhu AX	Phase 1/2 study of everolimus in advanced hepatocellular carcinoma.	Cancer	2011	54
21618573	207	You H	c-Met represents a potential therapeutic target for personalized treatment in hepatocellular carcinoma.	Hepatology	2011	56
22234835	207	Fang Y	MicroRNA-7 inhibits tumor growth and metastasis by targeting the phosphoinositide 3-kinase/Akt pathway in hepatocellular carcinoma.	Hepatology	2012	88
22577490	207	Longato L	Insulin resistance, ceramide accumulation, and endoplasmic reticulum stress in human chronic alcohol-related liver disease.	Oxidative medicine and cellular longevity	2012	32
22610073	207	Li XJ	As an independent unfavorable prognostic factor, IL-8 promotes metastasis of nasopharyngeal carcinoma through induction of epithelial-mesenchymal transition and activation of AKT signaling.	Carcinogenesis	2012	34
22898879	207	Wu K	Hepatic transforming growth factor beta gives rise to tumor-initiating cells and promotes liver cancer development.	Hepatology	2012	43
24194905	207	Chai ZT	MicroRNA-26a inhibits angiogenesis by down-regulating VEGFA through the PIK3C2α/Akt/HIF-1α pathway in hepatocellular carcinoma.	PloS one	2013	26
24467442	207	Hawley SA	Phosphorylation by Akt within the ST loop of AMPK-α1 down-regulates its activation in tumour cells.	The Biochemical journal	2014	26
24705351	207	Zhai B	Inhibition of Akt reverses the acquired resistance to sorafenib by switching protective autophagy to autophagic cell death in hepatocellular carcinoma.	Molecular cancer therapeutics	2014	36
25503676	207	Wei JX	Vps4A functions as a tumor suppressor by regulating the secretion and uptake of exosomal microRNAs in human hepatoma cells.	Hepatology	2015	19
8857851	213	Nakeeb A	Cholangiocarcinoma. A spectrum of intrahepatic, perihilar, and distal tumors.	Annals of surgery	1996	156
19736565	213	Song Z	Efficient generation of hepatocyte-like cells from human induced pluripotent stem cells.	Cell research	2009	113
21608000	213	Peng L	Autologous bone marrow mesenchymal stem cell transplantation in liver failure patients caused by hepatitis B: short-term and long-term outcomes.	Hepatology	2011	64
22230555	213	Fanali G	Human serum albumin: from bench to bedside.	Molecular aspects of medicine	2012	89
22550966	213	Huang AR	Medication-related falls in the elderly: causative factors and preventive strategies.	Drugs and aging	2012	47
24037576	213	Harimoto N	Sarcopenia as a predictor of prognosis in patients following hepatectomy for hepatocellular carcinoma.	The British journal of surgery	2013	31
24768475	213	Roberts JA	Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions.	The Lancet. Infectious diseases	2014	36
25500425	250	Hirschfield GM	Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid.	Gastroenterology	2015	46
11878923	335	Shi ST	Hepatitis C virus NS5A colocalizes with the core protein on lipid droplets and interacts with apolipoproteins.	Virology	2002	89
14592845	335	Rye KA	Formation and metabolism of prebeta-migrating, lipid-poor apolipoprotein A-I.	Arteriosclerosis, thrombosis, and vascular biology	2004	77
24388749	335	Halley P	Regulation of the apolipoprotein gene cluster by a long noncoding RNA.	Cell reports	2014	31
3621347	338	Powell LM	A novel form of tissue-specific RNA processing produces apolipoprotein-B48 in intestine.	Cell	1987	189
12668986	338	Musso G	Dietary habits and their relations to insulin resistance and postprandial lipemia in nonalcoholic steatohepatitis.	Hepatology	2003	117
16463046	338	Adiels M	Overproduction of large VLDL particles is driven by increased liver fat content in man.	Diabetologia	2006	107
16474148	338	Nielsen SU	Association between hepatitis C virus and very-low-density lipoprotein (VLDL)/LDL analyzed in iodixanol density gradients.	Journal of virology	2006	129
16597703	338	Ohsaki Y	Cytoplasmic lipid droplets are sites of convergence of proteasomal and autophagic degradation of apolipoprotein B.	Molecular biology of the cell	2006	66
17215532	338	Cuchel M	Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia.	The New England journal of medicine	2007	79
18223541	338	Williams KJ	Rapid regression of atherosclerosis: insights from the clinical and experimental literature.	Nature clinical practice. Cardiovascular medicine	2008	65
18242210	338	Fabbrini E	Alterations in adipose tissue and hepatic lipid kinetics in obese men and women with nonalcoholic fatty liver disease.	Gastroenterology	2008	98
19156195	338	Icard V	Secretion of hepatitis C virus envelope glycoproteins depends on assembly of apolipoprotein B positive lipoproteins.	PloS one	2009	47
19381015	338	Stanhope KL	Consuming fructose-sweetened, not glucose-sweetened, beverages increases visceral adiposity and lipids and decreases insulin sensitivity in overweight/obese humans.	The Journal of clinical investigation	2009	302
20227758	338	Raal FJ	Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial.	Lancet	2010	131
22213436	338	Sullivan S	Randomized trial of exercise effect on intrahepatic triglyceride content and lipid kinetics in nonalcoholic fatty liver disease.	Hepatology	2012	34
23060426	338	Stein EA	Apolipoprotein B synthesis inhibition with mipomersen in heterozygous familial hypercholesterolemia: results of a randomized, double-blind, placebo-controlled trial to assess efficacy and safety as add-on therapy in patients with coronary artery disease.	Circulation	2012	40
24013058	338	Thomas GS	Mipomersen, an apolipoprotein B synthesis inhibitor, reduces atherogenic lipoproteins in patients with severe hypercholesterolemia at high cardiovascular risk: a randomized, double-blind, placebo-controlled trial.	Journal of the American College of Cardiology	2013	30
24623100	338	Fenzl A	Circulating betatrophin correlates with atherogenic lipid profiles but not with glucose and insulin levels in insulin-resistant individuals.	Diabetologia	2014	37
24838241	338	Boyer A	The association of hepatitis C virus glycoproteins with apolipoproteins E and B early in assembly is conserved in lipoviral particles.	The Journal of biological chemistry	2014	21
25555214	338	Fabbrini E	Metabolically normal obese people are protected from adverse effects following weight gain.	The Journal of clinical investigation	2015	30
25756439	338	Besseling J	Association between familial hypercholesterolemia and prevalence of type 2 diabetes mellitus.	JAMA	2015	24
26210642	338	Tsimikas S	Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study.	Lancet	2015	44
8298639	540	Bull PC	The Wilson disease gene is a putative copper transporting P-type ATPase similar to the Menkes gene.	Nature genetics	1993	197
10498659	920	Benhamou Y	Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group.	Hepatology	1999	208
12493258	920	Thio CL	HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS).	Lancet	2002	211
14614606	920	Kamisawa T	A new clinicopathological entity of IgG4-related autoimmune disease.	Journal of gastroenterology	2003	132
16182404	920	Bräu N	Slower fibrosis progression in HIV/HCV-coinfected patients with successful HIV suppression using antiretroviral therapy.	Journal of hepatology	2006	89
16878047	920	Palella FJ Jr	Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study.	Journal of acquired immune deficiency syndromes	2006	382
17135583	920	Strategies for Management of Antiretroviral Therapy (SMART) Study Group.	CD4+ count-guided interruption of antiretroviral treatment.	The New England journal of medicine	2006	629
18198941	920	Denton PW	Antiretroviral pre-exposure prophylaxis prevents vaginal transmission of HIV-1 in humanized BLT mice.	PLoS medicine	2008	154
18427202	920	Baker JV	CD4+ count and risk of non-AIDS diseases following initial treatment for HIV infection.	AIDS	2008	106
18435450	920	Engels EA	Cancer risk in people infected with human immunodeficiency virus in the United States.	International journal of cancer	2008	221
18476292	920	Strategies for Management of Antiretroviral Therapy (SMART) Study Group.	Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study.	The Journal of infectious diseases	2008	123
19571723	920	Marin B	Non-AIDS-defining deaths and immunodeficiency in the era of combination antiretroviral therapy.	AIDS	2009	71
19818686	920	Guiguet M	Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study.	The Lancet. Oncology	2009	140
20380565	920	Antiretroviral Therapy Cohort Collaboration.	Causes of death in HIV-1-infected patients treated with antiretroviral therapy, 1996-2006: collaborative analysis of 13 HIV cohort studies.	Clinical infectious diseases 	2010	132
20453631	920	Data Collection on Adverse Events of Anti-HIV drugs (D:A:D) Study Group.	Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D Study.	AIDS	2010	121
21098232	920	Draper SJ	Enhancing blood-stage malaria subunit vaccine immunogenicity in rhesus macaques by combining adenovirus, poxvirus, and protein-in-adjuvant vaccines.	Journal of immunology	2010	49
21378535	920	Jani IV	Accurate CD4 T-cell enumeration and antiretroviral drug toxicity monitoring in primary healthcare clinics using point-of-care testing.	AIDS	2011	52
22547421	920	Babiker AG	Considerations in the rationale, design and methods of the Strategic Timing of AntiRetroviral Treatment (START) study.	Clinical trials	2013	55
22998068	920	Weber R	Decreasing mortality and changing patterns of causes of death in the Swiss HIV Cohort Study.	HIV medicine	2013	54
23596444	920	Hams E	The schistosoma granuloma: friend or foe?	Frontiers in immunology	2013	33
23886064	920	Lederman MM	Residual immune dysregulation syndrome in treated HIV infection.	Advances in immunology	2013	68
24602844	920	Grinsztejn B	Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trial.	The Lancet. Infectious diseases	2014	101
24771333	920	Ingle SM	Impact of risk factors for specific causes of death in the first and subsequent years of antiretroviral therapy among HIV-infected patients.	Clinical infectious diseases 	2014	25
25706092	920	Sulkowski MS	Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial.	JAMA	2015	65
26452565	920	Younas M	Immune activation in the course of HIV-1 infection: Causes, phenotypes and persistence under therapy.	HIV medicine	2016	16
26934227	920	Ma C	NAFLD causes selective CD4(+) T lymphocyte loss and promotes hepatocarcinogenesis.	Nature	2016	23
15517885	1026	Aggarwal BB	Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies.	Anticancer research	2004	196
20571512	1026	Wilting RH	Overlapping functions of Hdac1 and Hdac2 in cell cycle regulation and haematopoiesis.	The EMBO journal	2010	60
22108298	1026	Piotrowska H	Biological activity of piceatannol: leaving the shadow of resveratrol.	Mutation research	2012	41
22773548	1026	Chen HP	Metformin decreases hepatocellular carcinoma risk in a dose-dependent manner: population-based and in vitro studies.	Gut	2013	59
22895844	1026	Chiba M	Exosomes secreted from human colorectal cancer cell lines contain mRNAs, microRNAs and natural antisense RNAs, that can transfer into the human hepatoma HepG2 and lung cancer A549 cell lines.	Oncology reports	2012	46
24100703	1026	Sanli T	AMP-activated protein kinase (AMPK) beyond metabolism: a novel genomic stress sensor participating in the DNA damage response pathway.	Cancer biology and therapy	2014	37
25633810	1026	Ohta K	MicroRNA-93 activates c-Met/PI3K/Akt pathway activity in hepatocellular carcinoma by directly inhibiting PTEN and CDKN1A.	Oncotarget	2015	26
12937151	1029	Yang B	Aberrant promoter methylation profiles of tumor suppressor genes in hepatocellular carcinoma.	The American journal of pathology	2003	87
14507645	1029	Lee S	Aberrant CpG island hypermethylation along multistep hepatocarcinogenesis.	The American journal of pathology	2003	79
15082532	1029	Kalinichenko VV	Foxm1b transcription factor is essential for development of hepatocellular carcinomas and is negatively regulated by the p19ARF tumor suppressor.	Genes and development	2004	137
16799619	1029	Laurent-Puig P	Genetics of hepatocellular tumors.	Oncogene	2006	82
18161048	1029	Nishida N	Aberrant methylation of multiple tumor suppressor genes in aging liver, chronic hepatitis, and hepatocellular carcinoma.	Hepatology	2008	74
20146264	1029	Braconi C	MicroRNA-dependent regulation of DNA methyltransferase-1 and tumor suppressor gene expression by interleukin-6 in human malignant cholangiocytes.	Hepatology	2010	106
20876795	1029	Verna EC	Pancreatic cancer screening in a prospective cohort of high-risk patients: a comprehensive strategy of imaging and genetics.	Clinical cancer research 	2010	60
21145824	1029	Um TH	Aberrant CpG island hypermethylation in dysplastic nodules and early HCC of hepatitis B virus-related human multistep hepatocarcinogenesis.	Journal of hepatology	2011	41
22407776	1029	Nishida N	Characteristic patterns of altered DNA methylation predict emergence of human hepatocellular carcinoma.	Hepatology	2012	37
23505090	1029	Wang K	Genomic landscape of copy number aberrations enables the identification of oncogenic drivers in hepatocellular carcinoma.	Hepatology	2013	33
23746666	1029	Vermorken JB	Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial.	The Lancet. Oncology	2013	56
24798001	1029	Ahn SM	Genomic portrait of resectable hepatocellular carcinomas: implications of RB1 and FGF19 aberrations for patient stratification.	Hepatology	2014	45
25009010	1029	De Mattos-Arruda L	Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle.	Annals of oncology 	2014	47
25479140	1029	Grant RC	Prevalence of germline mutations in cancer predisposition genes in patients with pancreatic cancer.	Gastroenterology	2015	23
25536104	1029	Churi CR	Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications.	PloS one	2014	40
25822088	1029	Schulze K	Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets.	Nature genetics	2015	104
26024833	1029	Fu WM	Hotair mediates hepatocarcinogenesis through suppressing miRNA-218 expression and activating P14 and P16 signaling.	Journal of hepatology	2015	24
26099527	1029	Zucman-Rossi J	Genetic Landscape and Biomarkers of Hepatocellular Carcinoma.	Gastroenterology	2015	47
27213815	1029	Dauch D	A MYC-aurora kinase A protein complex represents an actionable drug target in p53-altered liver cancer.	Nature medicine	2016	15
2494700	1050	Landschulz WH	The DNA binding domain of the rat liver nuclear protein C/EBP is bipartite.	Science	1989	186
18326822	1050	Pinto JP	Erythropoietin mediates hepcidin expression in hepatocytes through EPOR signaling and regulation of C/EBPalpha.	Blood	2008	63
20110263	1050	van der Meer DL	Profiling of promoter occupancy by PPARalpha in human hepatoma cells via ChIP-chip analysis.	Nucleic acids research	2010	41
21038412	1050	Zeng C	A novel GSK-3 beta-C/EBP alpha-miR-122-insulin-like growth factor 1 receptor regulatory circuitry in human hepatocellular carcinoma.	Hepatology	2010	41
23665916	1050	Grøntved L	C/EBP maintains chromatin accessibility in liver and facilitates glucocorticoid receptor recruitment to steroid response elements.	The EMBO journal	2013	40
23769673	1050	Wang J	TRIB2 acts downstream of Wnt/TCF in liver cancer cells to regulate YAP and C/EBPα function.	Molecular cell	2013	33
24582926	1050	Du Y	Human hepatocytes with drug metabolic function induced from fibroblasts by lineage reprogramming.	Cell stem cell	2014	45
23386599	1066	Laizure SC	The role of human carboxylesterases in drug metabolism: have we overlooked their importance?	Pharmacotherapy	2013	29
26076923	1066	Wang X	CES1 genetic variation affects the activation of angiotensin-converting enzyme inhibitors.	The pharmacogenomics journal	2016	10
15925013	1071	Ginsberg HN	Regulation of plasma triglycerides in insulin resistance and diabetes.	Archives of medical research	2005	78
16365197	1071	Naik SU	Pharmacological activation of liver X receptors promotes reverse cholesterol transport in vivo.	Circulation	2006	87
7740812	1084	Scheele J	Resection of colorectal liver metastases.	World journal of surgery	1995	197
8608500	1084	Nordlinger B	Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Association Française de Chirurgie.	Cancer	1996	222
11274010	1084	Duffy MJ	Carcinoembryonic antigen as a marker for colorectal cancer: is it clinically useful?	Clinical chemistry	2001	94
15849507	1084	Pawlik TM	Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases.	Annals of surgery	2005	169
23572188	1084	Shimada H	Clinical significance of serum tumor markers for gastric cancer: a systematic review of literature by the Task Force of the Japanese Gastric Cancer Association.	Gastric cancer 	2014	32
16728727	1113	Rozengurt N	Colocalization of the alpha-subunit of gustducin with PYY and GLP-1 in L cells of human colon.	American journal of physiology. Gastrointestinal and liver physiology	2006	72
18603570	1113	Pape UF	Prognostic factors of long-term outcome in gastroenteropancreatic neuroendocrine tumours.	Endocrine-related cancer	2008	53
26499806	1244	Chen Z	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade.	Cancer letters	2016	26
26756674	1244	Bhise NS	A liver-on-a-chip platform with bioprinted hepatic spheroids.	Biofabrication	2016	20
17349844	1351	Shah SA	Recurrence after liver resection for hepatocellular carcinoma: risk factors, treatment, and outcomes.	Surgery	2007	66
20670867	1351	Englesbe MJ	Sarcopenia and mortality after liver transplantation.	Journal of the American College of Surgeons	2010	74
23382293	1351	Idilman IS	Hepatic steatosis: quantification by proton density fat fraction with MR imaging versus liver biopsy.	Radiology	2013	29
23426947	1351	McIntosh J	Therapeutic levels of FVIII following a single peripheral vein administration of rAAV vector encoding a novel human factor VIII variant.	Blood	2013	48
24062405	1351	Aizer AA	Marital status and survival in patients with cancer.	Journal of clinical oncology 	2013	86
25663689	1351	Hur K	Identification of a metastasis-specific MicroRNA signature in human colorectal cancer.	Journal of the National Cancer Institute	2015	34
6286115	1356	Nakabayashi H	Growth of human hepatoma cells lines with differentiated functions in chemically defined medium.	Cancer research	1982	423
11729749	1356	Kmieć Z	Cooperation of liver cells in health and disease.	Advances in anatomy, embryology, and cell biology	2001	99
25496901	1356	Bandmann O	Wilson's disease and other neurological copper disorders.	The Lancet. Neurology	2015	25
12021247	1401	Hundal RS	Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes.	The Journal of clinical investigation	2002	144
12366601	1401	Blake GJ	Inflammatory bio-markers and cardiovascular risk prediction.	Journal of internal medicine	2002	90
14581334	1401	Trikha M	Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence.	Clinical cancer research 	2003	102
14996776	1401	Nissen SE	Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial.	JAMA	2004	214
15201411	1401	Klein S	Absence of an effect of liposuction on insulin action and risk factors for coronary heart disease.	The New England journal of medicine	2004	113
15477419	1401	Latini R	Prognostic significance of the long pentraxin PTX3 in acute myocardial infarction.	Circulation	2004	80
16618517	1401	Haukeland JW	Systemic inflammation in nonalcoholic fatty liver disease is characterized by elevated levels of CCL2.	Journal of hepatology	2006	89
16952548	1401	Bekri S	Increased adipose tissue expression of hepcidin in severe obesity is independent from diabetes and NASH.	Gastroenterology	2006	88
17040956	1401	Wang Y	Lipocalin-2 is an inflammatory marker closely associated with obesity, insulin resistance, and hyperglycemia in humans.	Clinical chemistry	2007	91
17341558	1401	Balagopal P	Reduction of elevated serum retinol binding protein in obese children by lifestyle intervention: association with subclinical inflammation.	The Journal of clinical endocrinology and metabolism	2007	61
18054554	1401	Fraser A	Prevalence of elevated alanine aminotransferase among US adolescents and associated factors: NHANES 1999-2004.	Gastroenterology	2007	73
20021215	1401	Roxburgh CS	Role of systemic inflammatory response in predicting survival in patients with primary operable cancer.	Future oncology	2010	151
20181810	1401	Bakker GC	An antiinflammatory dietary mix modulates inflammation and oxidative and metabolic stress in overweight men: a nutrigenomics approach.	The American journal of clinical nutrition	2010	42
21266974	1401	Proctor MJ	An inflammation-based prognostic score (mGPS) predicts cancer survival independent of tumour site: a Glasgow Inflammation Outcome Study.	British journal of cancer	2011	66
21324198	1401	Koch A	Circulating soluble urokinase plasminogen activator receptor is stably elevated during the first week of treatment in the intensive care unit and predicts mortality in critically ill patients.	Critical care	2011	50
21525259	1401	Azadbakht L	The Dietary Approaches to Stop Hypertension eating plan affects C-reactive protein, coagulation abnormalities, and hepatic function tests among type 2 diabetic patients.	The Journal of nutrition	2011	40
21527524	1401	Galesloot TE	Serum hepcidin: reference ranges and biochemical correlates in the general population.	Blood	2011	45
22184371	1401	Tarhini AA	Safety and efficacy of combination immunotherapy with interferon alfa-2b and tremelimumab in patients with stage IV melanoma.	Journal of clinical oncology 	2012	33
22735432	1401	Ebbeling CB	Effects of dietary composition on energy expenditure during weight-loss maintenance.	JAMA	2012	59
23143785	1401	Gupta SC	Therapeutic roles of curcumin: lessons learned from clinical trials.	The AAPS journal	2013	133
23500256	1401	Khoury M	Role of the waist/height ratio in the cardiometabolic risk assessment of children classified by body mass index.	Journal of the American College of Cardiology	2013	26
23687099	1401	Neeland IJ	Associations of visceral and abdominal subcutaneous adipose tissue with markers of cardiac and metabolic risk in obese adults.	Obesity	2013	48
24269926	1401	Feagan BG	Methotrexate in combination with infliximab is no more effective than infliximab alone in patients with Crohn's disease.	Gastroenterology	2014	32
24443059	1401	Aleksandrova K	Inflammatory and metabolic biomarkers and risk of liver and biliary tract cancer.	Hepatology	2014	29
25190127	1401	Kinoshita A	The C-reactive protein/albumin ratio, a novel inflammation-based prognostic score, predicts outcomes in patients with hepatocellular carcinoma.	Annals of surgical oncology	2015	36
25341516	1401	Guarner V	Low-grade systemic inflammation connects aging, metabolic syndrome and cardiovascular disease.	Interdisciplinary topics in gerontology	2015	22
25517597	1401	Kopylov U	Small bowel capsule endoscopy in the management of established Crohn's disease: clinical impact, safety, and correlation with inflammatory biomarkers.	Inflammatory bowel diseases	2015	21
25589616	1401	Rossi JF	Interleukin-6 as a therapeutic target.	Clinical cancer research 	2015	38
25620670	1401	Wright EK	Measurement of fecal calprotectin improves monitoring and detection of recurrence of Crohn's disease after surgery.	Gastroenterology	2015	20
25683387	1401	Al Rifai M	The association of nonalcoholic fatty liver disease, obesity, and metabolic syndrome, with systemic inflammation and subclinical atherosclerosis: the Multi-Ethnic Study of Atherosclerosis (MESA).	Atherosclerosis	2015	20
25761863	1401	Michelena J	Systemic inflammatory response and serum lipopolysaccharide levels predict multiple organ failure and death in alcoholic hepatitis.	Hepatology	2015	26
26351344	1401	Hurwitz HI	Randomized, Double-Blind, Phase II Study of Ruxolitinib or Placebo in Combination With Capecitabine in Patients With Metastatic Pancreatic Cancer for Whom Therapy With Gemcitabine Has Failed.	Journal of clinical oncology 	2015	26
19236889	1432	Siu ER	Cadmium-induced testicular injury.	Toxicology and applied pharmacology	2009	54
19662154	1432	Samaga R	The logic of EGFR/ErbB signaling: theoretical properties and analysis of high-throughput data.	PLoS computational biology	2009	61
21931870	1432	Ivanov AV	Hepatitis C virus proteins activate NRF2/ARE pathway by distinct ROS-dependent and independent mechanisms in HUH7 cells.	PloS one	2011	38
22395444	1432	Sharma V	Zinc oxide nanoparticles induce oxidative DNA damage and ROS-triggered mitochondria mediated apoptosis in human liver cells (HepG2).	Apoptosis 	2012	46
24149188	1432	Felipo V	Hepatic encephalopathy: effects of liver failure on brain function.	Nature reviews. Neuroscience	2013	33
24349632	1432	Koul HK	Role of p38 MAP Kinase Signal Transduction in Solid Tumors.	Genes and cancer	2013	64
16087944	1493	Attia P	Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4.	Journal of clinical oncology 	2005	192
19247441	1493	Nakamoto N	Synergistic reversal of intrahepatic HCV-specific CD8 T cell exhaustion by combined PD-1/CTLA-4 blockade.	PLoS pathogens	2009	113
21074065	1493	Di Giacomo AM	The emerging toxicity profiles of anti-CTLA-4 antibodies across clinical indications.	Seminars in oncology	2010	52
23323154	1493	Hiniker SM	A systemic complete response of metastatic melanoma to local radiation and immunotherapy.	Translational oncology	2012	37
23341990	1493	Voskens CJ	The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network.	PloS one	2013	45
23466307	1493	Sangro B	A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C.	Journal of hepatology	2013	80
23960017	1493	Han Y	Human CD14+ CTLA-4+ regulatory dendritic cells suppress T-cell response by cytotoxic T-lymphocyte antigen-4-dependent IL-10 and indoleamine-2,3-dioxygenase production in hepatocellular carcinoma.	Hepatology	2014	26
24035405	1493	Calabrò L	Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial.	The Lancet. Oncology	2013	42
24388175	1493	Rong Z	An effective approach to prevent immune rejection of human ESC-derived allografts.	Cell stem cell	2014	25
25213377	1493	Kuehn HS	Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4.	Science	2014	83
25993145	1493	Postow MA	Managing immune checkpoint-blocking antibody side effects.	American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Meeting	2015	32
26765102	1493	Michot JM	Immune-related adverse events with immune checkpoint blockade: a comprehensive review.	European journal of cancer	2016	41
27141885	1493	Boutros C	Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination.	Nature reviews. Clinical oncology	2016	15
9990071	1499	Mann B	Target genes of beta-catenin-T cell-factor/lymphoid-enhancer-factor signaling in human colorectal carcinomas.	Proceedings of the National Academy of Sciences of the United States of America	1999	180
15072585	1499	Sugimura T	Heterocyclic amines: Mutagens/carcinogens produced during cooking of meat and fish.	Cancer science	2004	109
15480989	1499	Merle P	Functional consequences of frizzled-7 receptor overexpression in human hepatocellular carcinoma.	Gastroenterology	2004	72
15690474	1499	Sirica AE	Cholangiocarcinoma: molecular targeting strategies for chemoprevention and therapy.	Hepatology	2005	97
16039586	1499	Ding Q	Erk associates with and primes GSK-3beta for its inactivation resulting in upregulation of beta-catenin.	Molecular cell	2005	175
16799620	1499	Breuhahn K	Dysregulation of growth factor signaling in human hepatocellular carcinoma.	Oncogene	2006	99
16799625	1499	Levrero M	Viral hepatitis and liver cancer: the case of hepatitis C.	Oncogene	2006	107
16964294	1499	Zucman-Rossi J	Differential effects of inactivated Axin1 and activated beta-catenin mutations in human hepatocellular carcinomas.	Oncogene	2007	59
17187432	1499	Boyault S	Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets.	Hepatology	2007	191
17295177	1499	Villanueva A	Genomics and signaling pathways in hepatocellular carcinoma.	Seminars in liver disease	2007	150
17464972	1499	Thompson MD	WNT/beta-catenin signaling in liver health and disease.	Hepatology	2007	126
17545465	1499	Stoick-Cooper CL	Advances in signaling in vertebrate regeneration as a prelude to regenerative medicine.	Genes and development	2007	83
17785413	1499	Tward AD	Distinct pathways of genomic progression to benign and malignant tumors of the liver.	Proceedings of the National Academy of Sciences of the United States of America	2007	64
18006828	1499	Yamashita T	Activation of hepatic stem cell marker EpCAM by Wnt-beta-catenin signaling in hepatocellular carcinoma.	Cancer research	2007	113
18364678	1499	Qiao L	Suppression of tumorigenesis by human mesenchymal stem cells in a hepatoma model.	Cell research	2008	76
18519688	1499	Yang W	Wnt/beta-catenin signaling contributes to activation of normal and tumorigenic liver progenitor cells.	Cancer research	2008	101
18577996	1499	Bengochea A	Common dysregulation of Wnt/Frizzled receptor elements in human hepatocellular carcinoma.	British journal of cancer	2008	53
19061838	1499	Cairo S	Hepatic stem-like phenotype and interplay of Wnt/beta-catenin and Myc signaling in aggressive childhood liver cancer.	Cancer cell	2008	56
19585623	1499	Bioulac-Sage P	Hepatocellular adenoma management and phenotypic classification: the Bordeaux experience.	Hepatology	2009	54
19723656	1499	Hoshida Y	Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma.	Cancer research	2009	176
19797115	1499	Dennler S	Cloning of the human GLI2 Promoter: transcriptional activation by transforming growth factor-beta via SMAD3/beta-catenin cooperation.	The Journal of biological chemistry	2009	48
19852728	1499	van Zijl F	Epithelial-mesenchymal transition in hepatocellular carcinoma.	Future oncology	2009	78
21324318	1499	Toffanin S	MicroRNA-based classification of hepatocellular carcinoma and oncogenic role of miR-517a.	Gastroenterology	2011	53
21966251	1499	Nishida N	Genetic and epigenetic signatures in human hepatocellular carcinoma: a systematic review.	Current genomics	2011	40
22484120	1499	Zhang J	MicroRNA-26a promotes cholangiocarcinoma growth by activating β-catenin.	Gastroenterology	2012	47
22610915	1499	Zhang Y	Hepatitis C virus-induced up-regulation of microRNA-155 promotes hepatocarcinogenesis by activating Wnt signaling.	Hepatology	2012	74
23463346	1499	Beyoğlu D	Tissue metabolomics of hepatocellular carcinoma: tumor energy metabolism and the role of transcriptomic classification.	Hepatology	2013	37
23788652	1499	Kan Z	Whole-genome sequencing identifies recurrent mutations in hepatocellular carcinoma.	Genome research	2013	95
23887712	1499	Nault JC	High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions.	Nature communications	2013	82
24582836	1499	Lau CC	Viral-human chimeric transcript predisposes risk to liver cancer development and progression.	Cancer cell	2014	43
24589894	1499	Llovet JM	Hepatocellular carcinoma: reasons for phase III failure and novel perspectives on trial design.	Clinical cancer research 	2014	61
24837480	1499	Tao J	Activation of β-catenin and Yap1 in human hepatoblastoma and induction of hepatocarcinogenesis in mice.	Gastroenterology	2014	34
24859161	1499	Li L	Down-regulation of microRNA-494 via loss of SMAD4 increases FOXM1 and β-catenin signaling in pancreatic ductal adenocarcinoma cells.	Gastroenterology	2014	27
25248380	1499	Friemel J	Intratumor heterogeneity in hepatocellular carcinoma.	Clinical cancer research 	2015	28
25449213	1499	Cao C	The long intergenic noncoding RNA UFC1, a target of MicroRNA 34a, interacts with the mRNA stabilizing protein HuR to increase levels of β-catenin in HCC cells.	Gastroenterology	2015	37
25608619	1499	Zhang Z	microRNA-146a inhibits cancer metastasis by downregulating VEGF through dual pathways in hepatocellular carcinoma.	Molecular cancer	2015	18
25813403	1499	Leung WK	Wnt/β-Catenin activates MiR-183/96/182 expression in hepatocellular carcinoma that promotes cell invasion.	Cancer letters	2015	23
25871400	1499	Zhou Y	Salinomycin decreases doxorubicin resistance in hepatocellular carcinoma cells by inhibiting the β-catenin/TCF complex association via FOXO3a activation.	Oncotarget	2015	18
26811628	1499	Vilchez V	Targeting Wnt/β-catenin pathway in hepatocellular carcinoma treatment.	World journal of gastroenterology	2016	13
15331414	1543	Tateno C	Near completely humanized liver in mice shows human-type metabolic responses to drugs.	The American journal of pathology	2004	80
16112414	1543	Tsuchiya Y	Cytochrome P450-mediated metabolism of estrogens and its regulation in human.	Cancer letters	2005	90
16467132	1543	Paine MF	The human intestinal cytochrome P450 "pie".	Drug metabolism and disposition	2006	90
19514967	1543	Zhou SF	Polymorphism of human cytochrome P450 enzymes and its clinical impact.	Drug metabolism reviews	2009	86
23333322	1543	Zanger UM	Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation.	Pharmacology and therapeutics	2013	180
16176115	1544	Anderson GD	Pregnancy-induced changes in pharmacokinetics: a mechanistic-based approach.	Clinical pharmacokinetics	2005	130
17241619	1544	Guillouzo A	The human hepatoma HepaRG cells: a highly differentiated model for studies of liver metabolism and toxicity of xenobiotics.	Chemico-biological interactions	2007	61
18160535	1544	Lee MY	Three-dimensional cellular microarray for high-throughput toxicology assays.	Proceedings of the National Academy of Sciences of the United States of America	2008	66
19414633	1544	Mega JL	Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes.	Circulation	2009	70
19651758	1544	Fisher CD	Hepatic cytochrome P450 enzyme alterations in humans with progressive stages of nonalcoholic fatty liver disease.	Drug metabolism and disposition	2009	63
19812348	1544	Kazui M	Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite.	Drug metabolism and disposition	2010	93
19877180	1544	Sullivan GJ	Generation of functional human hepatic endoderm from human induced pluripotent stem cells.	Hepatology	2010	110
23132334	1544	Reese MJ	In vitro investigations into the roles of drug transporters and metabolizing enzymes in the disposition and drug interactions of dolutegravir, a HIV integrase inhibitor.	Drug metabolism and disposition	2013	35
21994437	1548	Ohtsuki S	Simultaneous absolute protein quantification of transporters, cytochromes P450, and UDP-glucuronosyltransferases as a novel approach for the characterization of individual human liver: comparison with mRNA levels and activities.	Drug metabolism and disposition	2012	42
24440487	1548	Schwartz RE	Pluripotent stem cell-derived hepatocyte-like cells.	Biotechnology advances	2014	43
8035341	1555	Shimada T	Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians.	The Journal of pharmacology and experimental therapeutics	1994	224
11437235	1555	Anzenbacher P	Cytochromes P450 and metabolism of xenobiotics.	Cellular and molecular life sciences 	2001	94
11470993	1555	Lang T	Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver.	Pharmacogenetics	2001	100
12676886	1555	Ward BA	The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity.	The Journal of pharmacology and experimental therapeutics	2003	140
12867492	1555	Wilkening S	Comparison of primary human hepatocytes and hepatoma cell line Hepg2 with regard to their biotransformation properties.	Drug metabolism and disposition	2003	78
14618296	1555	Zanger UM	Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry.	Naunyn-Schmiedeberg's archives of pharmacology	2004	122
15159443	1555	Desta Z	Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6.	The Journal of pharmacology and experimental therapeutics	2004	119
17464996	1555	Cai J	Directed differentiation of human embryonic stem cells into functional hepatic cells.	Hepatology	2007	137
17559344	1555	Desta Z	Impact of CYP2B6 polymorphism on hepatic efavirenz metabolism in vitro.	Pharmacogenomics	2007	60
17638512	1555	Zanger UM	Polymorphic CYP2B6: molecular mechanisms and emerging clinical significance.	Pharmacogenomics	2007	63
18781911	1555	Wang H	CYP2B6: new insights into a historically overlooked cytochrome P450 isozyme.	Current drug metabolism	2008	85
20538623	1555	Yang X	Systematic genetic and genomic analysis of cytochrome P450 enzyme activities in human liver.	Genome research	2010	69
21145849	1555	Begriche K	Drug-induced toxicity on mitochondria and lipid metabolism: mechanistic diversity and deleterious consequences for the liver.	Journal of hepatology	2011	44
21505298	1555	Yuan J	Toxicogenomics of nevirapine-associated cutaneous and hepatic adverse events among populations of African, Asian, and European descent.	AIDS	2011	38
23467454	1555	Zanger UM	Pharmacogenetics of cytochrome P450 2B6 (CYP2B6): advances on polymorphisms, mechanisms, and clinical relevance.	Frontiers in genetics	2013	25
27039104	1555	Heslop JA	Mechanistic evaluation of primary human hepatocyte culture using global proteomic analysis reveals a selective dedifferentiation profile.	Archives of toxicology	2017	6
12222994	1557	Desta Z	Clinical significance of the cytochrome P450 2C19 genetic polymorphism.	Clinical pharmacokinetics	2002	112
12551730	1557	Vaswani M	Role of selective serotonin reuptake inhibitors in psychiatric disorders: a comprehensive review.	Progress in neuro-psychopharmacology and biological psychiatry	2003	85
15258107	1557	Li XQ	Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities.	Drug metabolism and disposition	2004	80
16413245	1557	Sim SC	A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants.	Clinical pharmacology and therapeutics	2006	114
18171251	1557	Pascual A	Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes.	Clinical infectious diseases 	2008	130
14676196	1558	Schoch GA	Structure of human microsomal cytochrome P450 2C8. Evidence for a peripheral fatty acid binding site.	The Journal of biological chemistry	2004	72
16714062	1558	Shitara Y	Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions.	Pharmacology and therapeutics	2006	65
12882588	1559	Niemi M	Pharmacokinetic interactions with rifampicin : clinical relevance.	Clinical pharmacokinetics	2003	98
21852944	1559	Cojocaru V	Structure and dynamics of the membrane-bound cytochrome P450 2C9.	PLoS computational biology	2011	43
14652237	1565	Stearns V	Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine.	Journal of the National Cancer Institute	2003	163
19629072	1565	Hoskins JM	CYP2D6 and tamoxifen: DNA matters in breast cancer.	Nature reviews. Cancer	2009	70
19817501	1565	Zhou SF	Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I.	Clinical pharmacokinetics	2009	80
22205192	1565	Crews KR	Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for codeine therapy in the context of cytochrome P450 2D6 (CYP2D6) genotype.	Clinical pharmacology and therapeutics	2012	78
25457200	1565	Baxter M	Phenotypic and functional analyses show stem cell-derived hepatocyte-like cells better mimic fetal rather than adult hepatocytes.	Journal of hepatology	2015	26
14556645	1571	Videla LA	Oxidative stress-related parameters in the liver of non-alcoholic fatty liver disease patients.	Clinical science	2004	73
14744237	1571	Caro AA	Oxidative stress, toxicology, and pharmacology of CYP2E1.	Annual review of pharmacology and toxicology	2004	81
16455479	1571	Boffetta P	Alcohol and cancer.	The Lancet. Oncology	2006	134
16923312	1571	Albano E	Alcohol, oxidative stress and free radical damage.	The Proceedings of the Nutrition Society	2006	88
20067334	1571	Hanley MJ	Effect of obesity on the pharmacokinetics of drugs in humans.	Clinical pharmacokinetics	2010	68
21664213	1571	Aubert J	Increased expression of cytochrome P450 2E1 in nonalcoholic fatty liver disease: mechanisms and pathophysiological role.	Clinics and research in hepatology and gastroenterology	2011	45
22271347	1571	D'Ambrosio R	A morphometric and immunohistochemical study to assess the benefit of a sustained virological response in hepatitis C virus patients with cirrhosis.	Hepatology	2012	36
10570062	1576	Goodwin B	The orphan human pregnane X receptor mediates the transcriptional activation of CYP3A4 by rifampicin through a distal enhancer module.	Molecular pharmacology	1999	98
10852961	1576	Moore LB	St. John's wort induces hepatic drug metabolism through activation of the pregnane X receptor.	Proceedings of the National Academy of Sciences of the United States of America	2000	100
11248086	1576	Xie W	An essential role for nuclear receptors SXR/PXR in detoxification of cholestatic bile acids.	Proceedings of the National Academy of Sciences of the United States of America	2001	124
16122278	1576	Peng B	Clinical pharmacokinetics of imatinib.	Clinical pharmacokinetics	2005	67
16581329	1576	Law M	Statin safety: a systematic review.	The American journal of cardiology	2006	97
17097610	1576	Suetsugu A	Characterization of CD133+ hepatocellular carcinoma cells as cancer stem/progenitor cells.	Biochemical and biophysical research communications	2006	141
17215845	1576	Glaeser H	Intestinal drug transporter expression and the impact of grapefruit juice in humans.	Clinical pharmacology and therapeutics	2007	64
18268015	1576	Takagi S	Post-transcriptional regulation of human pregnane X receptor by micro-RNA affects the expression of cytochrome P450 3A4.	The Journal of biological chemistry	2008	65
18288078	1576	Hebert MF	Effects of pregnancy on CYP3A and P-glycoprotein activities as measured by disposition of midazolam and digoxin: a University of Washington specialized center of research study.	Clinical pharmacology and therapeutics	2008	52
18292207	1576	Agarwal S	Efficient differentiation of functional hepatocytes from human embryonic stem cells.	Stem cells	2008	95
18473749	1576	Zhou SF	Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4.	Current drug metabolism	2008	71
19022918	1576	Aurich H	Hepatocyte differentiation of mesenchymal stem cells from human adipose tissue in vitro promotes hepatic integration in vivo.	Gut	2009	72
19159124	1576	Golomb BA	Statin adverse effects : a review of the literature and evidence for a mitochondrial mechanism.	American journal of cardiovascular drugs 	2008	78
19228077	1576	Keating GM	Sorafenib: a review of its use in advanced hepatocellular carcinoma.	Drugs	2009	70
19483103	1576	Waxman DJ	Sex differences in the expression of hepatic drug metabolizing enzymes.	Molecular pharmacology	2009	123
19514965	1576	Klotz U	Pharmacokinetics and drug metabolism in the elderly.	Drug metabolism reviews	2009	45
20170205	1576	Staatz CE	Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part I.	Clinical pharmacokinetics	2010	44
20386561	1576	Wang D	Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs.	The pharmacogenomics journal	2011	81
22095466	1576	Chen YF	Rapid generation of mature hepatocyte-like cells from human induced pluripotent stem cells by an efficient three-step protocol.	Hepatology	2012	65
12815072	1581	Holt JA	Definition of a novel growth factor-dependent signal cascade for the suppression of bile acid biosynthesis.	Genes and development	2003	155
17116003	1581	Lundåsen T	Circulating intestinal fibroblast growth factor 19 has a pronounced diurnal variation and modulates hepatic bile acid synthesis in man.	Journal of internal medicine	2006	91
19185005	1581	Schaap FG	High expression of the bile salt-homeostatic hormone fibroblast growth factor 19 in the liver of patients with extrahepatic cholestasis.	Hepatology	2009	52
19346330	1581	Chiang JY	Bile acids: regulation of synthesis.	Journal of lipid research	2009	214
20301097	1581	Touboul T	Generation of functional hepatocytes from human embryonic stem cells under chemically defined conditions that recapitulate liver development.	Hepatology	2010	119
23299969	1581	Bechmann LP	Free fatty acids repress small heterodimer partner (SHP) activation and adiponectin counteracts bile acid-induced liver injury in superobese patients with nonalcoholic steatohepatitis.	Hepatology	2013	30
25705637	1581	Ali AH	Recent advances in the development of farnesoid X receptor agonists.	Annals of translational medicine	2015	20
19185000	1737	Lleo A	Apotopes and the biliary specificity of primary biliary cirrhosis.	Hepatology	2009	57
20568301	1737	Lleo A	Biliary apotopes and anti-mitochondrial antibodies activate innate immune responses in primary biliary cirrhosis.	Hepatology	2010	55
23347352	1737	Hirschfield GM	The immunobiology and pathophysiology of primary biliary cirrhosis.	Annual review of pathology	2013	39
19557413	1803	Cordero OJ	On the origin of serum CD26 and its altered concentration in cancer patients.	Cancer immunology, immunotherapy 	2009	52
20569697	1803	Pang R	A subpopulation of CD26+ cancer stem cells with metastatic capacity in human colorectal cancer.	Cell stem cell	2010	127
21812507	1803	Baetta R	Pharmacology of dipeptidyl peptidase-4 inhibitors: similarities and differences.	Drugs	2011	39
21824266	1803	D'Alessio D	The role of dysregulated glucagon secretion in type 2 diabetes.	Diabetes, obesity and metabolism	2011	48
10722725	1956	Jo M	Cross-talk between epidermal growth factor receptor and c-Met signal pathways in transformed cells.	The Journal of biological chemistry	2000	104
12124174	1956	Liu D	EGFR is a transducer of the urokinase receptor initiated signal that is required for in vivo growth of a human carcinoma.	Cancer cell	2002	103
16170173	1956	Philip PA	Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer.	Journal of clinical oncology 	2005	94
17030071	1956	Malhi H	Cholangiocarcinoma: modern advances in understanding a deadly old disease.	Journal of hepatology	2006	65
17050876	1956	Dragovich T	Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127.	Journal of clinical oncology 	2006	75
17283074	1956	Hsu SC	Characterization of a novel tripartite nuclear localization sequence in the EGFR family.	The Journal of biological chemistry	2007	83
17623837	1956	Thomas MB	Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma.	Cancer	2007	69
18087285	1956	Yoshikawa D	Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma.	British journal of cancer	2008	79
18381447	1956	Fuchs BC	Epithelial-to-mesenchymal transition and integrin-linked kinase mediate sensitivity to epidermal growth factor receptor inhibition in human hepatoma cells.	Cancer research	2008	86
18821591	1956	Llovet JM	Molecular targeted therapies in hepatocellular carcinoma.	Hepatology	2008	267
19169683	1956	Ramanathan RK	A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer.	Cancer chemotherapy and pharmacology	2009	59
19421193	1956	Bos PD	Genes that mediate breast cancer metastasis to the brain.	Nature	2009	433
19706799	1956	Desbois-Mouthon C	Insulin-like growth factor-1 receptor inhibition induces a resistance mechanism via the epidermal growth factor receptor/HER3/AKT signaling pathway: rational basis for cotargeting insulin-like growth factor-1 receptor and epidermal growth factor receptor in hepatocellular carcinoma.	Clinical cancer research 	2009	57
19942479	1956	Folprecht G	Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial.	The Lancet. Oncology	2010	131
20022809	1956	Mitsudomi T	Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial.	The Lancet. Oncology	2010	783
20736298	1956	Cameron D	Lapatinib plus capecitabine in women with HER-2-positive advanced breast cancer: final survival analysis of a phase III randomized trial.	The oncologist	2010	49
20940188	1956	Sequist LV	Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer.	Journal of clinical oncology 	2010	100
21253578	1956	Gu TL	Survey of tyrosine kinase signaling reveals ROS kinase fusions in human cholangiocarcinoma.	PloS one	2011	89
21783417	1956	Zhou C	Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study.	The Lancet. Oncology	2011	709
21914172	1956	Sihto H	Breast cancer biological subtypes and protein expression predict for the preferential distant metastasis sites: a nationwide cohort study.	Breast cancer research 	2011	40
22173549	1956	Vermaat JS	Primary colorectal cancers and their subsequent hepatic metastases are genetically different: implications for selection of patients for targeted treatment.	Clinical cancer research 	2012	44
22178589	1956	Andersen JB	Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors.	Gastroenterology	2012	76
22282022	1956	Doebele RC	Oncogene status predicts patterns of metastatic spread in treatment-naive nonsmall cell lung cancer.	Cancer	2012	48
22414764	1956	Blivet-Van Eggelpoël MJ	Epidermal growth factor receptor and HER-3 restrict cell response to sorafenib in hepatocellular carcinoma cells.	Journal of hepatology	2012	37
22454081	1956	Gallardo A	Increased signalling of EGFR and IGF1R, and deregulation of PTEN/PI3K/Akt pathway are related with trastuzumab resistance in HER2 breast carcinomas.	British journal of cancer	2012	55
22535374	1956	De Boeck A	Bone marrow-derived mesenchymal stem cells promote colorectal cancer progression through paracrine neuregulin 1/HER3 signalling.	Gut	2013	34
23021375	1956	Berg M	EGFR and downstream genetic alterations in KRAS/BRAF and PI3K/AKT pathways in colorectal cancer: implications for targeted therapy.	Discovery medicine	2012	32
23045285	1956	Gusenbauer S	HGF induces novel EGFR functions involved in resistance formation to tyrosine kinase inhibitors.	Oncogene	2013	35
23233388	1956	Mostert B	KRAS and BRAF mutation status in circulating colorectal tumor cells and their correlation with primary and metastatic tumor tissue.	International journal of cancer	2013	30
23391413	1956	Voss JS	Molecular profiling of cholangiocarcinoma shows potential for targeted therapy treatment decisions.	Human pathology	2013	38
23407558	1956	Yu HA	Local therapy with continued EGFR tyrosine kinase inhibitor therapy as a treatment strategy in EGFR-mutant advanced lung cancers that have developed acquired resistance to EGFR tyrosine kinase inhibitors.	Journal of thoracic oncology 	2013	48
23633480	1956	Chettouh H	Mitogenic insulin receptor-A is overexpressed in human hepatocellular carcinoma due to EGFR-mediated dysregulation of RNA splicing factors.	Cancer research	2013	32
24122263	1956	Cummings MC	Metastatic progression of breast cancer: insights from 50 years of autopsies.	The Journal of pathology	2014	25
24384534	1956	Maroun CR	The Met receptor tyrosine kinase: a key player in oncogenesis and drug resistance.	Pharmacology and therapeutics	2014	31
24550739	1956	Borad MJ	Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma.	PLoS genetics	2014	55
24656976	1956	Yan M	HER2 aberrations in cancer: implications for therapy.	Cancer treatment reviews	2014	40
24677197	1956	Fuchs BC	Epidermal growth factor receptor inhibition attenuates liver fibrosis and development of hepatocellular carcinoma.	Hepatology	2014	60
24687833	1956	Schwartzberg LS	PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer.	Journal of clinical oncology 	2014	99
24919569	1956	Van Cutsem E	Randomized phase Ib/II trial of rilotumumab or ganitumab with panitumumab versus panitumumab alone in patients with wild-type KRAS metastatic colorectal cancer.	Clinical cancer research 	2014	22
25409146	1956	Cheng CJ	MicroRNA silencing for cancer therapy targeted to the tumour microenvironment.	Nature	2015	97
25639985	1956	Mao C	Concordant analysis of KRAS, BRAF, PIK3CA mutations, and PTEN expression between primary colorectal cancer and matched metastases.	Scientific reports	2015	19
25726255	1956	Higuchi C	Identification of circulating miR-101, miR-375 and miR-802 as biomarkers for type 2 diabetes.	Metabolism	2015	20
25738220	1956	Sholl LM	Multi-institutional Oncogenic Driver Mutation Analysis in Lung Adenocarcinoma: The Lung Cancer Mutation Consortium Experience.	Journal of thoracic oncology 	2015	37
25979833	1956	Brulé SY	Location of colon cancer (right-sided versus left-sided) as a prognostic factor and a predictor of benefit from cetuximab in NCIC CO.17.	European journal of cancer	2015	22
26184520	1956	Tabernero J	Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial.	The Lancet. Oncology	2015	37
26644315	1956	Russo M	Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer.	Cancer discovery	2016	23
26724471	1956	Lin JJ	Five-Year Survival in EGFR-Mutant Metastatic Lung Adenocarcinoma Treated with EGFR-TKIs.	Journal of thoracic oncology 	2016	12
26890676	1956	Veitch AM	Endoscopy in patients on antiplatelet or anticoagulant therapy, including direct oral anticoagulants: British Society of Gastroenterology (BSG) and European Society of Gastrointestinal Endoscopy (ESGE) guidelines.	Endoscopy	2016	12
27083334	1956	Park K	Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial.	The Lancet. Oncology	2016	46
2062846	2056	Semenza GL	Hypoxia-inducible nuclear factors bind to an enhancer element located 3' to the human erythropoietin gene.	Proceedings of the National Academy of Sciences of the United States of America	1991	144
12393428	2056	Weinstein DA	Inappropriate expression of hepcidin is associated with iron refractory anemia: implications for the anemia of chronic disease.	Blood	2002	104
17393520	2056	Wurmbach E	Genome-wide molecular profiles of HCV-induced dysplasia and hepatocellular carcinoma.	Hepatology	2007	173
17488680	2056	Origa R	Liver iron concentrations and urinary hepcidin in beta-thalassemia.	Haematologica	2007	81
18324962	2056	Arcasoy MO	The non-haematopoietic biological effects of erythropoietin.	British journal of haematology	2008	78
21127173	2056	England SJ	Immature erythroblasts with extensive ex vivo self-renewal capacity emerge from the early mammalian fetus.	Blood	2011	44
23291219	2056	Haase VH	Regulation of erythropoiesis by hypoxia-inducible factors.	Blood reviews	2013	57
23669289	2056	Hézode C	Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890.	Journal of hepatology	2013	96
23994384	2056	Coilly A	Safety and efficacy of protease inhibitors to treat hepatitis C after liver transplantation: a multicenter experience.	Journal of hepatology	2014	37
24645943	2056	Kamar N	Ribavirin for chronic hepatitis E virus infection in transplant recipients.	The New England journal of medicine	2014	44
25218788	2056	Gordon SC	Safety profile of boceprevir and telaprevir in chronic hepatitis C: real world experience from HCV-TARGET.	Journal of hepatology	2015	21
25535770	2056	Salvagno GL	Red blood cell distribution width: A simple parameter with multiple clinical applications.	Critical reviews in clinical laboratory sciences	2015	34
26976799	2056	Pockros PJ	Efficacy of Direct-Acting Antiviral Combination for Patients With Hepatitis C Virus Genotype 1 Infection and Severe Renal Impairment or End-Stage Renal Disease.	Gastroenterology	2016	18
17569205	2064	Aggarwal BB	Curcumin: the Indian solid gold.	Advances in experimental medicine and biology	2007	179
18981013	2064	Luu TH	A phase II trial of vorinostat (suberoylanilide hydroxamic acid) in metastatic breast cancer: a California Cancer Consortium study.	Clinical cancer research 	2008	59
20357763	2064	Dijkers EC	Biodistribution of 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer.	Clinical pharmacology and therapeutics	2010	145
20421541	2064	Krop IE	Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer.	Journal of clinical oncology 	2010	102
20498394	2064	Kennecke H	Metastatic behavior of breast cancer subtypes.	Journal of clinical oncology 	2010	290
20863372	2064	Hoefnagel LD	Receptor conversion in distant breast cancer metastases.	Breast cancer research 	2010	49
21642515	2064	Pierga JY	High independent prognostic and predictive value of circulating tumor cells compared with serum tumor markers in a large prospective trial in first-line chemotherapy for metastatic breast cancer patients.	Annals of oncology 	2012	59
21671017	2064	Harrell JC	Genomic analysis identifies unique signatures predictive of brain, lung, and liver relapse.	Breast cancer research and treatment	2012	73
22124109	2064	Niikura N	Loss of human epidermal growth factor receptor 2 (HER2) expression in metastatic sites of HER2-overexpressing primary breast tumors.	Journal of clinical oncology 	2012	67
22178456	2064	Amir E	Tissue confirmation of disease recurrence in breast cancer patients: pooled analysis of multi-centre, multi-disciplinary prospective studies.	Cancer treatment reviews	2012	32
22257673	2064	Baselga J	Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial.	Lancet	2012	207
22493419	2064	Guarneri V	Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHER-LOB study.	Journal of clinical oncology 	2012	58
22689179	2064	Janjigian YY	Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis.	Annals of oncology 	2012	46
22966038	2064	Liby KT	Synthetic oleanane triterpenoids: multifunctional drugs with a broad range of applications for prevention and treatment of chronic disease.	Pharmacological reviews	2012	69
24337604	2064	Mortimer JE	Functional imaging of human epidermal growth factor receptor 2-positive metastatic breast cancer using (64)Cu-DOTA-trastuzumab PET.	Journal of nuclear medicine 	2014	28
24665085	2064	Sörensen J	First-in-human molecular imaging of HER2 expression in breast cancer metastases using the 111In-ABY-025 affibody molecule.	Journal of nuclear medicine 	2014	36
25130998	2064	de Azambuja E	Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response.	The Lancet. Oncology	2014	44
26449837	2064	Keyaerts M	Phase I Study of 68Ga-HER2-Nanobody for PET/CT Assessment of HER2 Expression in Breast Carcinoma.	Journal of nuclear medicine 	2016	18
26530965	2064	Murtaza M	Multifocal clonal evolution characterized using circulating tumour DNA in a case of metastatic breast cancer.	Nature communications	2015	33
26598744	2064	Piccart-Gebhart M	Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial.	Journal of clinical oncology 	2016	17
27009855	2064	Böger C	PD-L1 is an independent prognostic predictor in gastric cancer of Western patients.	Oncotarget	2016	23
15701910	2147	Albers GW	Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial.	JAMA	2005	72
17764540	2147	Eriksson BI	Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial.	Journal of thrombosis and haemostasis 	2007	105
17869635	2147	Eriksson BI	Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial.	Lancet	2007	124
17950801	2147	Ezekowitz MD	Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study).	The American journal of cardiology	2007	56
18006647	2147	Blech S	The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans.	Drug metabolism and disposition	2008	82
18399711	2147	Stangier J	Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate.	Clinical pharmacokinetics	2008	88
18534438	2147	RE-MOBILIZE Writing Committee.	Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery.	The Journal of arthroplasty	2009	79
19696042	2147	Stangier J	Pharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor.	Clinical and applied thrombosis/hemostasis 	2009	46
19717844	2147	Connolly SJ	Dabigatran versus warfarin in patients with atrial fibrillation.	The New England journal of medicine	2009	1020
19966341	2147	Schulman S	Dabigatran versus warfarin in the treatment of acute venous thromboembolism.	The New England journal of medicine	2009	236
21225098	2147	Eriksson BI	Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II*). A randomised, double-blind, non-inferiority trial.	Thrombosis and haemostasis	2011	58
11435577	2158	Nakai H	Extrachromosomal recombinant adeno-associated virus vector genomes are primarily responsible for stable liver transduction in vivo.	Journal of virology	2001	98
16322469	2158	Nathwani AC	Self-complementary adeno-associated virus vectors containing a novel liver-specific human factor IX expression cassette enable highly efficient transduction of murine and nonhuman primate liver.	Blood	2006	111
16474400	2158	Manno CS	Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response.	Nature medicine	2006	528
16868252	2158	Jiang H	Effects of transient immunosuppression on adenoassociated, virus-mediated, liver-directed gene transfer in rhesus macaques and implications for human gene therapy.	Blood	2006	99
17090654	2158	Nathwani AC	Safe and efficient transduction of the liver after peripheral vein infusion of self-complementary AAV vector results in stable therapeutic expression of human FIX in nonhuman primates.	Blood	2007	97
17609423	2158	Mingozzi F	Modulation of tolerance to the transgene product in a nonhuman primate model of AAV-mediated gene transfer to liver.	Blood	2007	72
17979678	2158	Mingozzi F	Immune responses to AAV in clinical trials.	Current gene therapy	2007	76
21245849	2158	Nathwani AC	Long-term safety and efficacy following systemic administration of a self-complementary AAV vector encoding human FIX pseudotyped with serotype 5 and 8 capsid proteins.	Molecular therapy 	2011	79
22149959	2158	Nathwani AC	Adenovirus-associated virus vector-mediated gene transfer in hemophilia B.	The New England journal of medicine	2011	424
25419787	2158	Monahan PE	Employing a gain-of-function factor IX variant R338L to advance the efficacy and safety of hemophilia B human gene therapy: preclinical evaluation supporting an ongoing adeno-associated virus clinical trial.	Human gene therapy	2015	16
18094680	2168	Portilla D	Liver fatty acid-binding protein as a biomarker of acute kidney injury after cardiac surgery.	Kidney international	2008	80
22093507	2168	Krawczeski CD	Temporal relationship and predictive value of urinary acute kidney injury biomarkers after pediatric cardiopulmonary bypass.	Journal of the American College of Cardiology	2011	51
23599408	2168	Parikh CR	Performance of kidney injury molecule-1 and liver fatty acid-binding protein and combined biomarkers of AKI after cardiac surgery.	Clinical journal of the American Society of Nephrology 	2013	43
23689653	2168	McCullough PA	Diagnosis of acute kidney injury using functional and injury biomarkers: workgroup statements from the tenth Acute Dialysis Quality Initiative Consensus Conference.	Contributions to nephrology	2013	33
24375576	2168	Belcher JM	Kidney biomarkers and differential diagnosis of patients with cirrhosis and acute kidney injury.	Hepatology	2014	30
25316431	2168	Fufaa GD	Association of urinary KIM-1, L-FABP, NAG and NGAL with incident end-stage renal disease and mortality in American Indians with type 2 diabetes mellitus.	Diabetologia	2015	16
25882434	2168	Basu RK	Assessment of Worldwide Acute Kidney Injury, Renal Angina and Epidemiology in critically ill children (AWARE): study protocol for a prospective observational study.	BMC nephrology	2015	15
10657556	2244	Yudkin JS	Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link?	Atherosclerosis	2000	214
20943795	2244	Mozaffarian D	Circulating palmitoleic acid and risk of metabolic abnormalities and new-onset diabetes.	The American journal of clinical nutrition	2010	43
21799891	2244	Bonetto A	STAT3 activation in skeletal muscle links muscle wasting and the acute phase response in cancer cachexia.	PloS one	2011	58
22144540	2244	Zhang YZ	Hemorrhagic fever caused by a novel Bunyavirus in China: pathogenesis and correlates of fatal outcome.	Clinical infectious diseases 	2012	52
22385985	2244	Adinolfi LE	Chronic HCV infection is a risk of atherosclerosis. Role of HCV and HCV-related steatosis.	Atherosclerosis	2012	35
23352505	2244	Kostadinova R	A long-term three dimensional liver co-culture system for improved prediction of clinically relevant drug-induced hepatotoxicity.	Toxicology and applied pharmacology	2013	37
8008069	2475	Brown EJ	A mammalian protein targeted by G1-arresting rapamycin-receptor complex.	Nature	1994	400
15604215	2475	Khamzina L	Increased activation of the mammalian target of rapamycin pathway in liver and skeletal muscle of obese rats: possible involvement in obesity-linked insulin resistance.	Endocrinology	2005	141
17666010	2475	Tremblay F	Role of dietary proteins and amino acids in the pathogenesis of insulin resistance.	Annual review of nutrition	2007	58
18174523	2475	Fraenkel M	mTOR inhibition by rapamycin prevents beta-cell adaptation to hyperglycemia and exacerbates the metabolic state in type 2 diabetes.	Diabetes	2008	95
18184959	2475	Bissler JJ	Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis.	The New England journal of medicine	2008	278
18393362	2475	Yin XM	Autophagy in the liver.	Hepatology	2008	69
18722871	2475	Curatolo P	Tuberous sclerosis.	Lancet	2008	152
18929564	2475	Villanueva A	Pivotal role of mTOR signaling in hepatocellular carcinoma.	Gastroenterology	2008	182
19223493	2475	Yu G	Overexpression of phosphorylated mammalian target of rapamycin predicts lymph node metastasis and prognosis of chinese patients with gastric cancer.	Clinical cancer research 	2009	47
19301157	2475	Zhou L	The mTOR pathway is associated with the poor prognosis of human hepatocellular carcinoma.	Medical oncology	2010	43
19948145	2475	Laplante M	An emerging role of mTOR in lipid biosynthesis.	Current biology 	2009	144
20501828	2475	Fornari F	MiR-199a-3p regulates mTOR and c-Met to influence the doxorubicin sensitivity of human hepatocarcinoma cells.	Cancer research	2010	120
20659474	2475	Ding WX	Autophagy reduces acute ethanol-induced hepatotoxicity and steatosis in mice.	Gastroenterology	2010	130
20664473	2475	Boudreaux JP	The NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: well-differentiated neuroendocrine tumors of the Jejunum, Ileum, Appendix, and Cecum.	Pancreas	2010	53
20810672	2475	Memmott RM	Metformin prevents tobacco carcinogen--induced lung tumorigenesis.	Cancer prevention research	2010	129
20860370	2475	Liu Q	Discovery of 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzoh1,6naphthyridin-2(1H)-one as a highly potent, selective mammalian target of rapamycin (mTOR) inhibitor for the treatment of cancer.	Journal of medicinal chemistry	2010	63
21269838	2475	Howell JJ	mTOR couples cellular nutrient sensing to organismal metabolic homeostasis.	Trends in endocrinology and metabolism	2011	107
21322566	2475	Liu Q	Discovery of 9-(6-aminopyridin-3-yl)-1-(3-(trifluoromethyl)phenyl)benzoh1,6naphthyridin-2(1H)-one (Torin2) as a potent, selective, and orally available mammalian target of rapamycin (mTOR) inhibitor for treatment of cancer.	Journal of medicinal chemistry	2011	47
22014210	2475	Deblon N	Chronic mTOR inhibition by rapamycin induces muscle insulin resistance despite weight loss in rats.	British journal of pharmacology	2012	44
22408252	2475	Tan SH	Induction of autophagy by palmitic acid via protein kinase C-mediated signaling pathway independent of mTOR (mammalian target of rapamycin).	The Journal of biological chemistry	2012	41
22449814	2475	Bakan I	Connecting mTORC1 signaling to SREBP-1 activation.	Current opinion in lipidology	2012	36
22562464	2475	Luo Z	The Nedd8-activating enzyme inhibitor MLN4924 induces autophagy and apoptosis to suppress liver cancer cell growth.	Cancer research	2012	60
22983984	2475	Iwaya T	Downregulation of miR-144 is associated with colorectal cancer progression via activation of mTOR signaling pathway.	Carcinogenesis	2012	41
22994652	2475	Welker MW	Recurrent hepatocellular carcinoma after liver transplantation - an emerging clinical challenge.	Transplant international 	2013	29
23832089	2475	Pajvani UB	Inhibition of Notch uncouples Akt activation from hepatic lipid accumulation by decreasing mTorc1 stability.	Nature medicine	2013	32
23929677	2475	Sinha RA	Caffeine stimulates hepatic lipid metabolism by the autophagy-lysosomal pathway in mice.	Hepatology	2014	36
24308993	2475	Matter MS	Targeting the mTOR pathway in hepatocellular carcinoma: current state and future trends.	Journal of hepatology	2014	36
24606899	2475	Solon-Biet SM	The ratio of macronutrients, not caloric intake, dictates cardiometabolic health, aging, and longevity in ad libitum-fed mice.	Cell metabolism	2014	121
25554914	2475	Albert V	mTOR signaling in cellular and organismal energetics.	Current opinion in cell biology	2015	49
25902704	2475	Longo VD	Interventions to Slow Aging in Humans: Are We Ready?	Aging cell	2015	58
26627594	2475	Qian P	The Dlk1-Gtl2 Locus Preserves LT-HSC Function by Inhibiting the PI3K-mTOR Pathway to Restrict Mitochondrial Metabolism.	Cell stem cell	2016	13
15707893	2494	Krylova IN	Structural analyses reveal phosphatidyl inositols as ligands for the NR5 orphan receptors SF-1 and LRH-1.	Cell	2005	133
19587243	2538	Samuel VT	Fasting hyperglycemia is not associated with increased expression of PEPCK or G6Pc in patients with Type 2 Diabetes.	Proceedings of the National Academy of Sciences of the United States of America	2009	47
20159955	2538	Schmutz I	The mammalian clock component PERIOD2 coordinates circadian output by interaction with nuclear receptors.	Genes and development	2010	107
21565617	2538	Mihaylova MM	Class IIa histone deacetylases are hormone-activated regulators of FOXO and mammalian glucose homeostasis.	Cell	2011	140
15919803	2641	Franklin I	Beta-cell secretory products activate alpha-cell ATP-dependent potassium channels to inhibit glucagon release.	Diabetes	2005	74
19930006	2641	Jendle J	Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue.	Diabetes, obesity and metabolism	2009	46
20876708	2641	Musso G	Obesity, diabetes, and gut microbiota: the hygiene hypothesis expanded?	Diabetes care	2010	105
22467277	2641	Nobili V	Hepatic progenitor cells activation, fibrosis, and adipokines production in pediatric nonalcoholic fatty liver disease.	Hepatology	2012	31
22538359	2641	Dirksen C	Mechanisms of improved glycaemic control after Roux-en-Y gastric bypass.	Diabetologia	2012	35
22915024	2641	Rodgers RJ	Anti-obesity drugs: past, present and future.	Disease models and mechanisms	2012	45
24738701	2641	Alisi A	Randomised clinical trial: The beneficial effects of VSL#3 in obese children with non-alcoholic steatohepatitis.	Alimentary pharmacology and therapeutics	2014	30
24988476	2641	Napolitano A	Novel gut-based pharmacology of metformin in patients with type 2 diabetes mellitus.	PloS one	2014	28
26394161	2641	Armstrong MJ	Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis.	Journal of hepatology	2016	13
15016359	2645	Kamata K	Structural basis for allosteric regulation of the monomeric allosteric enzyme human glucokinase.	Structure	2004	94
18556336	2645	Vaxillaire M	The common P446L polymorphism in GCKR inversely modulates fasting glucose and triglyceride levels and reduces type 2 diabetes risk in the DESIR prospective general French population.	Diabetes	2008	53
18726182	2645	Iynedjian PB	Molecular physiology of mammalian glucokinase.	Cellular and molecular life sciences 	2009	77
19373249	2645	Matschinsky FM	Assessing the potential of glucokinase activators in diabetes therapy.	Nature reviews. Drug discovery	2009	90
19643913	2645	Beer NL	The P446L variant in GCKR associated with fasting plasma glucose and triglyceride levels exerts its effect through increased glucokinase activity in liver.	Human molecular genetics	2009	97
9441573	2688	Papanicolaou DA	The pathophysiologic roles of interleukin-6 in human disease.	Annals of internal medicine	1998	132
16543404	2688	Waxman DJ	Growth hormone regulation of sex-dependent liver gene expression.	Molecular endocrinology	2006	115
19240267	2688	Møller N	Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects.	Endocrine reviews	2009	133
23303913	2688	Tchernof A	Pathophysiology of human visceral obesity: an update.	Physiological reviews	2013	212
24825400	2688	Chia DJ	Minireview: mechanisms of growth hormone-mediated gene regulation.	Molecular endocrinology	2014	22
19496787	2719	Shirakawa H	Glypican-3 expression is correlated with poor prognosis in hepatocellular carcinoma.	Cancer science	2009	53
22577059	2719	Sawada Y	Phase I trial of a glypican-3-derived peptide vaccine for advanced hepatocellular carcinoma: immunologic evidence and potential for improving overall survival.	Clinical cancer research 	2012	57
23362325	2719	Zhu AX	First-in-man phase I study of GC33, a novel recombinant humanized antibody against glypican-3, in patients with advanced hepatocellular carcinoma.	Clinical cancer research 	2013	39
25123086	2719	Nault JC	Telomerase reverse transcriptase promoter mutation is an early somatic genetic alteration in the transformation of premalignant nodules in hepatocellular carcinoma on cirrhosis.	Hepatology	2014	37
9738173	2875	-	Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group.	Pediatrics	1998	307
9819447	2875	Davis GL	Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group.	The New England journal of medicine	1998	152
10210705	2875	Kenny-Walsh E	Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group.	The New England journal of medicine	1999	144
10632283	2875	Sulkowski MS	Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection.	JAMA	2000	119
11438497	2875	Dixon JB	Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese.	Gastroenterology	2001	176
12093239	2875	Prati D	Updated definitions of healthy ranges for serum alanine aminotransferase levels.	Annals of internal medicine	2002	219
12512031	2875	Ruhl CE	Determinants of the association of overweight with elevated serum alanine aminotransferase activity in the United States.	Gastroenterology	2003	118
12606734	2875	Hadziyannis SJ	Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B.	The New England journal of medicine	2003	131
12809815	2875	Clark JM	The prevalence and etiology of elevated aminotransferase levels in the United States.	The American journal of gastroenterology	2003	255
14512888	2875	Neuschwander-Tetri BA	Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone.	Hepatology	2003	99
14699491	2875	Peters MG	Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B.	Gastroenterology	2004	90
14960526	2875	Hickman IJ	Modest weight loss and physical activity in overweight patients with chronic liver disease results in sustained improvements in alanine aminotransferase, fasting insulin, and quality of life.	Gut	2004	72
15361502	2875	Chan HL	Genotype C hepatitis B virus infection is associated with an increased risk of hepatocellular carcinoma.	Gut	2004	100
15639293	2875	Janssen HL	Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial.	Lancet	2005	150
15867021	2875	Schwimmer JB	Influence of gender, race, and ethnicity on suspected fatty liver in obese adolescents.	Pediatrics	2005	81
15871997	2875	Yuen MF	Prognostic determinants for chronic hepatitis B in Asians: therapeutic implications.	Gut	2005	74
16391218	2875	Chen CJ	Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level.	JAMA	2006	452
16682043	2875	Schindhelm RK	Alanine aminotransferase predicts coronary heart disease events: a 10-year follow-up of the Hoorn Study.	Atherosclerosis	2007	72
16820551	2875	Watkins PB	Aminotransferase elevations in healthy adults receiving 4 grams of acetaminophen daily: a randomized controlled trial.	JAMA	2006	74
17021358	2875	Saukkonen JJ	An official ATS statement: hepatotoxicity of antituberculosis therapy.	American journal of respiratory and critical care medicine	2006	137
17077998	2875	Flaig TW	A phase I and pharmacokinetic study of silybin-phytosome in prostate cancer patients.	Investigational new drugs	2007	56
17087951	2875	Hadziyannis SJ	Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years.	Gastroenterology	2006	145
17439526	2875	Coco B	Transient elastography: a new surrogate marker of liver fibrosis influenced by major changes of transaminases.	Journal of viral hepatitis	2007	108
17595248	2875	Kotronen A	Liver fat in the metabolic syndrome.	The Journal of clinical endocrinology and metabolism	2007	70
18095306	2875	Arena U	Acute viral hepatitis increases liver stiffness values measured by transient elastography.	Hepatology	2008	107
18384521	2875	Leite NC	Prevalence and associated factors of non-alcoholic fatty liver disease in patients with type-2 diabetes mellitus.	Liver international 	2009	76
18421281	2875	Larson-Meyer DE	Effect of 6-month calorie restriction and exercise on serum and liver lipids and markers of liver function.	Obesity	2008	53
18624899	2875	Banas A	Rapid hepatic fate specification of adipose-derived stem cells and their therapeutic potential for liver failure.	Journal of gastroenterology and hepatology	2009	63
18673426	2875	Chan HL	Alanine aminotransferase-based algorithms of liver stiffness measurement by transient elastography (Fibroscan) for liver fibrosis in chronic hepatitis B.	Journal of viral hepatitis	2009	66
18752331	2875	Fracanzani AL	Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes.	Hepatology	2008	95
18945255	2875	Loomba R	Clinical trial: pilot study of metformin for the treatment of non-alcoholic steatohepatitis.	Alimentary pharmacology and therapeutics	2009	48
19010326	2875	Goessling W	Aminotransferase levels and 20-year risk of metabolic syndrome, diabetes, and cardiovascular disease.	Gastroenterology	2008	61
19131466	2875	Fraser A	Alanine aminotransferase, gamma-glutamyltransferase, and incident diabetes: the British Women's Heart and Health Study and meta-analysis.	Diabetes care	2009	71
19523535	2875	Shah AG	Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease.	Clinical gastroenterology and hepatology 	2009	84
19585618	2875	Feldstein AE	Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study.	Hepatology	2009	123
19877169	2875	Ratziu V	Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial.	Hepatology	2010	52
20064512	2875	Schwimmer JB	SAFETY study: alanine aminotransferase cutoff values are set too high for reliable detection of pediatric chronic liver disease.	Gastroenterology	2010	46
20858492	2875	Williams CD	Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study.	Gastroenterology	2011	346
20959817	2875	Yin J	Association between the various mutations in viral core promoter region to different stages of hepatitis B, ranging of asymptomatic carrier state to hepatocellular carcinoma.	The American journal of gastroenterology	2011	38
21109302	2875	Athyros VG	Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis.	Lancet	2010	95
21126940	2875	Cave M	Polychlorinated biphenyls, lead, and mercury are associated with liver disease in American adults: NHANES 2003-2004.	Environmental health perspectives	2010	45
21139063	2875	Thomson EC	Predicting spontaneous clearance of acute hepatitis C virus in a large cohort of HIV-1-infected men.	Gut	2011	38
21145828	2875	Ratziu V	A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis.	Journal of hepatology	2011	48
21323729	2875	Chen CJ	Natural history of chronic hepatitis B REVEALed.	Journal of gastroenterology and hepatology	2011	39
21423260	2875	Kwon H	Hepatitis B therapy.	Nature reviews. Gastroenterology and hepatology	2011	66
21497551	2875	Yang HI	Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score.	The Lancet. Oncology	2011	67
21505361	2875	Vajro P	Effects of Lactobacillus rhamnosus strain GG in pediatric obesity-related liver disease.	Journal of pediatric gastroenterology and nutrition	2011	47
21521847	2875	Lavine JE	Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial.	JAMA	2011	155
21602530	2875	Wong VW	Coronary artery disease and cardiovascular outcomes in patients with non-alcoholic fatty liver disease.	Gut	2011	38
21688282	2875	Bhala N	The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: an international collaborative study.	Hepatology	2011	78
21846782	2875	Wong VW	Prevalence of non-alcoholic fatty liver disease and advanced fibrosis in Hong Kong Chinese: a population study using proton-magnetic resonance spectroscopy and transient elastography.	Gut	2012	62
21953442	2875	Kowdley KV	Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease.	Hepatology	2012	65
21971536	2875	Rizzo L	Comparison of transient elastography and acoustic radiation force impulse for non-invasive staging of liver fibrosis in patients with chronic hepatitis C.	The American journal of gastroenterology	2011	39
22023985	2875	Parker HM	Omega-3 supplementation and non-alcoholic fatty liver disease: a systematic review and meta-analysis.	Journal of hepatology	2012	73
22183689	2875	Lomonaco R	Effect of adipose tissue insulin resistance on metabolic parameters and liver histology in obese patients with nonalcoholic fatty liver disease.	Hepatology	2012	52
22266604	2875	Antoine DJ	Molecular forms of HMGB1 and keratin-18 as mechanistic biomarkers for mode of cell death and prognosis during clinical acetaminophen hepatotoxicity.	Journal of hepatology	2012	103
22271511	2875	Kim D	Nonalcoholic fatty liver disease is associated with coronary artery calcification.	Hepatology	2012	55
22362824	2875	van der Lely AJ	Long-term safety of pegvisomant in patients with acromegaly: comprehensive review of 1288 subjects in ACROSTUDY.	The Journal of clinical endocrinology and metabolism	2012	31
22546742	2875	Karlsson CL	The microbiota of the gut in preschool children with normal and excessive body weight.	Obesity	2012	64
22894884	2875	Di Giacomo AM	Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial.	The Lancet. Oncology	2012	46
22941922	2875	Tseng TC	Serum hepatitis B surface antigen levels help predict disease progression in patients with low hepatitis B virus loads.	Hepatology	2013	32
23355498	2875	Loomba R	Synergism between obesity and alcohol in increasing the risk of hepatocellular carcinoma: a prospective cohort study.	American journal of epidemiology	2013	25
23696515	2875	Noureddin M	Utility of magnetic resonance imaging versus histology for quantifying changes in liver fat in nonalcoholic fatty liver disease trials.	Hepatology	2013	53
24107395	2875	Gordon SC	Antiviral therapy for chronic hepatitis B virus infection and development of hepatocellular carcinoma in a US population.	Clinical gastroenterology and hepatology 	2014	25
24187469	2875	Ma YY	Effects of probiotics on nonalcoholic fatty liver disease: a meta-analysis.	World journal of gastroenterology	2013	46
24316260	2875	Lambert JE	Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease.	Gastroenterology	2014	63
24401715	2875	Eslamparast T	Synbiotic supplementation in nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled pilot study.	The American journal of clinical nutrition	2014	25
24569542	2875	Chiu S	Effect of fructose on markers of non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of controlled feeding trials.	European journal of clinical nutrition	2014	28
25092309	2875	Ward J	Circulating microRNA profiles in human patients with acetaminophen hepatotoxicity or ischemic hepatitis.	Proceedings of the National Academy of Sciences of the United States of America	2014	34
25311610	2875	Faghihzadeh F	Resveratrol supplementation improves inflammatory biomarkers in patients with nonalcoholic fatty liver disease.	Nutrition research	2014	24
25482832	2875	Loomba R	Ezetimibe for the treatment of nonalcoholic steatohepatitis: assessment by novel magnetic resonance imaging and magnetic resonance elastography in a randomized trial (MOZART trial).	Hepatology	2015	36
25776943	2875	Guo K	Serum betatrophin concentrations are significantly increased in overweight but not in obese or type 2 diabetic individuals.	Obesity	2015	15
25873639	2875	Kwok R	Screening diabetic patients for non-alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements: a prospective cohort study.	Gut	2016	13
26171685	2875	Koehler EM	Presence of diabetes mellitus and steatosis is associated with liver stiffness in a general population: The Rotterdam study.	Hepatology	2016	11
26512983	2875	Anderson EL	The Prevalence of Non-Alcoholic Fatty Liver Disease in Children and Adolescents: A Systematic Review and Meta-Analysis.	PloS one	2015	22
26667191	2875	Ballestri S	Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta-analysis.	Journal of gastroenterology and hepatology	2016	25
18304676	3052	Llovet JM	Novel advancements in the management of hepatocellular carcinoma in 2008.	Journal of hepatology	2008	186
19115377	3052	Paradis V	Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: a pathological analysis.	Hepatology	2009	67
20059340	3052	Villanueva A	Hepatocellular carcinoma: novel molecular approaches for diagnosis, prognosis, and therapy.	Annual review of medicine	2010	61
22178270	3052	Scisciani C	Transcriptional regulation of miR-224 upregulated in human HCCs by NFκB inflammatory pathways.	Journal of hepatology	2012	33
24275343	3052	Chaiteerakij R	Update on biomarkers of hepatocellular carcinoma.	Clinical gastroenterology and hepatology 	2015	18
25559230	3052	Lee YJ	Hepatocellular carcinoma: diagnostic performance of multidetector CT and MR imaging-a systematic review and meta-analysis.	Radiology	2015	23
26752112	3052	Xue R	Variable Intra-Tumor Genomic Heterogeneity of Multiple Lesions in Patients With Hepatocellular Carcinoma.	Gastroenterology	2016	13
11473047	3077	Marchesini G	Nonalcoholic fatty liver disease: a feature of the metabolic syndrome.	Diabetes	2001	377
11812557	3077	Beutler E	Penetrance of 845G--&amp;gt; A (C282Y) HFE hereditary haemochromatosis mutation in the USA.	Lancet	2002	114
12105842	3077	Bugianesi E	Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma.	Gastroenterology	2002	247
15858186	3077	Adams PC	Hemochromatosis and iron-overload screening in a racially diverse population.	The New England journal of medicine	2005	132
18199861	3077	Allen KJ	Iron-overload-related disease in HFE hereditary hemochromatosis.	The New England journal of medicine	2008	98
19254567	3077	Gao J	Interaction of the hereditary hemochromatosis protein HFE with transferrin receptor 2 is required for transferrin-induced hepcidin expression.	Cell metabolism	2009	93
19931264	3077	Valenti L	HFE genotype, parenchymal iron accumulation, and liver fibrosis in patients with nonalcoholic fatty liver disease.	Gastroenterology	2010	47
2531289	3082	Nakamura T	Molecular cloning and expression of human hepatocyte growth factor.	Nature	1989	282
12865405	3082	Kollet O	HGF, SDF-1, and MMP-9 are involved in stress-induced human CD34+ stem cell recruitment to the liver.	The Journal of clinical investigation	2003	127
15562440	3082	Lee KD	In vitro hepatic differentiation of human mesenchymal stem cells.	Hepatology	2004	168
16410389	3082	Son BR	Migration of bone marrow and cord blood mesenchymal stem cells in vitro is regulated by stromal-derived factor-1-CXCR4 and hepatocyte growth factor-c-met axes and involves matrix metalloproteinases.	Stem cells	2006	146
17638846	3082	Denny MF	Interferon-alpha promotes abnormal vasculogenesis in lupus: a potential pathway for premature atherosclerosis.	Blood	2007	73
19318488	3082	Eder JP	Novel therapeutic inhibitors of the c-Met signaling pathway in cancer.	Clinical cancer research 	2009	133
19542190	3082	McLarty J	Tea polyphenols decrease serum levels of prostate-specific antigen, hepatocyte growth factor, and vascular endothelial growth factor in prostate cancer patients and inhibit production of hepatocyte growth factor and vascular endothelial growth factor in vitro.	Cancer prevention research	2009	66
23388504	3082	Goyal L	Targeting the HGF/c-MET pathway in hepatocellular carcinoma.	Clinical cancer research 	2013	46
24259426	3082	Yang X	MicroRNA-26a suppresses angiogenesis in human hepatocellular carcinoma by targeting hepatocyte growth factor-cMet pathway.	Hepatology	2014	42
8387214	3091	Wang GL	General involvement of hypoxia-inducible factor 1 in transcriptional response to hypoxia.	Proceedings of the National Academy of Sciences of the United States of America	1993	255
8756616	3091	Forsythe JA	Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1.	Molecular and cellular biology	1996	763
15349906	3091	Lee JS	Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling.	Hepatology	2004	192
20463368	3091	Michelakis ED	Metabolic modulation of glioblastoma with dichloroacetate.	Science translational medicine	2010	188
20665378	3091	Rosmorduc O	Hypoxia: a link between fibrogenesis, angiogenesis, and carcinogenesis in liver disease.	Seminars in liver disease	2010	46
21712410	3091	Mathieu J	HIF induces human embryonic stem cell markers in cancer cells.	Cancer research	2011	139
22055506	3091	Nandal A	Activation of the HIF prolyl hydroxylase by the iron chaperones PCBP1 and PCBP2.	Cell metabolism	2011	41
22885334	3091	Chen Y	Hedgehog controls hepatic stellate cell fate by regulating metabolism.	Gastroenterology	2012	40
23358852	3091	Zhang Q	Wnt/β-catenin signaling enhances hypoxia-induced epithelial-mesenchymal transition in hepatocellular carcinoma via crosstalk with hif-1α signaling.	Carcinogenesis	2013	35
23496980	3091	Zhang L	Hypoxia induces epithelial-mesenchymal transition via activation of SNAI1 by hypoxia-inducible factor -1α in hepatocellular carcinoma.	BMC cancer	2013	48
23533994	3091	Capece D	The inflammatory microenvironment in hepatocellular carcinoma: a pivotal role for tumor-associated macrophages.	BioMed research international	2013	58
23954640	3091	Sun K	Fibrosis and adipose tissue dysfunction.	Cell metabolism	2013	90
24434214	3091	Li J	Cbx4 governs HIF-1α to potentiate angiogenesis of hepatocellular carcinoma by its SUMO E3 ligase activity.	Cancer cell	2014	24
24550282	3091	Faubert B	Loss of the tumor suppressor LKB1 promotes metabolic reprogramming of cancer cells via HIF-1α.	Proceedings of the National Academy of Sciences of the United States of America	2014	38
26054020	3091	Guo W	MiR-199a-5p is negatively associated with malignancies and regulates glycolysis and lactate production by targeting hexokinase 2 in liver cancer.	Hepatology	2015	16
26365179	3091	Dupuy F	PDK1-Dependent Metabolic Reprogramming Dictates Metastatic Potential in Breast Cancer.	Cell metabolism	2015	31
26837767	3091	Ye LY	Hypoxia-Induced Epithelial-to-Mesenchymal Transition in Hepatocellular Carcinoma Induces an Immunosuppressive Tumor Microenvironment to Promote Metastasis.	Cancer research	2016	17
8945471	3172	Yamagata K	Mutations in the hepatocyte nuclear factor-4alpha gene in maturity-onset diabetes of the young (MODY1)	Nature	1996	210
14988562	3172	Odom DT	Control of pancreas and liver gene expression by HNF transcription factors.	Science	2004	407
19440305	3172	Yuan X	Identification of an endogenous ligand bound to a native orphan nuclear receptor.	PloS one	2009	67
20158877	3172	Koh W	Analysis of deep sequencing microRNA expression profile from human embryonic stem cells derived mesenchymal stem cells reveals possible role of let-7 microRNA family in downstream targeting of hepatic nuclear factor 4 alpha.	BMC genomics	2010	40
21852396	3172	DeLaForest A	HNF4A is essential for specification of hepatic progenitors from human pluripotent stem cells.	Development	2011	49
22068426	3172	Takayama K	Efficient generation of functional hepatocytes from human embryonic stem cells and induced pluripotent stem cells by HNF4α transduction.	Molecular therapy 	2012	54
22153071	3172	Hatziapostolou M	An HNF4α-miRNA inflammatory feedback circuit regulates hepatocellular oncogenesis.	Cell	2011	137
23485969	3172	Chandra V	Multidomain integration in the structure of the HNF-4α nuclear receptor complex.	Nature	2013	39
24752868	3172	Ning BF	Hepatocyte nuclear factor 4α-nuclear factor-κB feedback circuit modulates liver cancer progression.	Hepatology	2014	21
15625368	3439	McDermott DF	Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma.	Journal of clinical oncology 	2005	104
17326216	3439	Bruno S	Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study.	Hepatology	2007	119
17353365	3439	Dunn C	Cytokines induced during chronic hepatitis B virus infection promote a pathway for NK cell-mediated liver damage.	The Journal of experimental medicine	2007	102
20335250	3439	Mordstein M	Lambda interferon renders epithelial cells of the respiratory and gastrointestinal tracts resistant to viral infections.	Journal of virology	2010	98
21199525	3439	Yuen MF	Treatment of chronic hepatitis B: Evolution over two decades.	Journal of gastroenterology and hepatology	2011	43
21800339	3439	Marukian S	Hepatitis C virus induces interferon-λ and interferon-stimulated genes in primary liver cultures.	Hepatology	2011	85
22806323	3439	Lai CL	Prevention of hepatitis B virus-related hepatocellular carcinoma with antiviral therapy.	Hepatology	2013	35
22878466	3439	Schaefer M	Hepatitis C infection, antiviral treatment and mental health: a European expert consensus statement.	Journal of hepatology	2012	34
25733157	3439	Gane EJ	The oral toll-like receptor-7 agonist GS-9620 in patients with chronic hepatitis B virus infection.	Journal of hepatology	2015	25
25754160	3439	Serti E	Successful Interferon-Free Therapy of Chronic Hepatitis C Virus Infection Normalizes Natural Killer Cell Function.	Gastroenterology	2015	19
16234567	3440	Yeo W	A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma.	Journal of the National Cancer Institute	2005	108
19669255	3440	Liaw YF	Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update.	Hepatology international	2008	211
24983321	3440	Meissner EG	Endogenous intrahepatic IFNs and association with IFN-free HCV treatment outcome.	The Journal of clinical investigation	2014	25
10438971	3458	Heeger PS	Pretransplant frequency of donor-specific, IFN-gamma-producing lymphocytes is a manifestation of immunologic memory and correlates with the risk of posttransplant rejection episodes.	Journal of immunology	1999	111
10646872	3458	Jaiswal M	Inflammatory cytokines induce DNA damage and inhibit DNA repair in cholangiocarcinoma cells by a nitric oxide-dependent mechanism.	Cancer research	2000	104
11170064	3458	To KF	Pathology of fatal human infection associated with avian influenza A H5N1 virus.	Journal of medical virology	2001	104
12001037	3458	Libraty DH	Differing influences of virus burden and immune activation on disease severity in secondary dengue-3 virus infections.	The Journal of infectious diseases	2002	160
15100412	3458	Wieland S	Genomic analysis of the host response to hepatitis B virus infection.	Proceedings of the National Academy of Sciences of the United States of America	2004	143
16547287	3458	Longhi MS	Functional study of CD4+CD25+ regulatory T cells in health and autoimmune hepatitis.	Journal of immunology	2006	64
16785573	3458	Xu D	Circulating and liver resident CD4+CD25+ regulatory T cells actively influence the antiviral immune response and disease progression in patients with hepatitis B.	Journal of immunology	2006	101
17379663	3458	Heidel JD	Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNA.	Proceedings of the National Academy of Sciences of the United States of America	2007	87
17916356	3458	Dolganiuc A	Viral and host factors induce macrophage activation and loss of toll-like receptor tolerance in chronic HCV infection.	Gastroenterology	2007	65
19542050	3458	Gao B	Liver natural killer and natural killer T cells: immunobiology and emerging roles in liver diseases.	Journal of leukocyte biology	2009	93
19747917	3458	Ahlenstiel G	Natural killer cells are polarized toward cytotoxicity in chronic hepatitis C in an interferon-alfa-dependent manner.	Gastroenterology	2010	91
20881185	3458	Silverman JM	Leishmania exosomes modulate innate and adaptive immune responses through effects on monocytes and dendritic cells.	Journal of immunology	2010	56
21187913	3458	Peppa D	Blockade of immunosuppressive cytokines restores NK cell antiviral function in chronic hepatitis B virus infection.	PLoS pathogens	2010	64
24967632	3458	Jo J	Toll-like receptor 8 agonist and bacteria trigger potent activation of innate immune cells in human liver.	PLoS pathogens	2014	29
25387892	3458	Chen S	Combination of 4-1BB agonist and PD-1 antagonist promotes antitumor effector/memory CD8 T cells in a poorly immunogenic tumor model.	Cancer immunology research	2015	17
25644696	3458	Jiang W	Dysbiosis gut microbiota associated with inflammation and impaired mucosal immune function in intestine of humans with non-alcoholic fatty liver disease.	Scientific reports	2015	23
25647269	3458	Talaat RM	Th1/Th2/Th17/Treg cytokine imbalance in systemic lupus erythematosus (SLE) patients: Correlation with disease activity.	Cytokine	2015	23
8156941	3479	Thissen JP	Nutritional regulation of the insulin-like growth factors.	Endocrine reviews	1994	133
19620249	3479	Vigneri P	Diabetes and cancer.	Endocrine-related cancer	2009	187
20197302	3479	Perrini S	The GH/IGF1 axis and signaling pathways in the muscle and bone: mechanisms underlying age-related skeletal muscle wasting and osteoporosis.	The Journal of endocrinology	2010	62
20345478	3479	Tsugane S	Insulin resistance and cancer: epidemiological evidence.	Cancer science	2010	42
21911725	3479	Kaseb AO	Clinical and prognostic implications of plasma insulin-like growth factor-1 and vascular endothelial growth factor in patients with hepatocellular carcinoma.	Journal of clinical oncology 	2011	39
22701472	3479	Arcidiacono B	Insulin resistance and cancer risk: an overview of the pathogenetic mechanisms.	Experimental diabetes research	2012	64
3264384	3558	Rosenberg SA	Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report.	The New England journal of medicine	1988	246
11022927	3558	Takayama T	Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial.	Lancet	2000	135
12218168	3558	Wedemeyer H	Impaired effector function of hepatitis C virus-specific CD8+ T cells in chronic hepatitis C virus infection.	Journal of immunology	2002	173
12663797	3558	Wherry EJ	Viral persistence alters CD8 T-cell immunodominance and tissue distribution and results in distinct stages of functional impairment.	Journal of virology	2003	484
14974943	3558	Opelz G	Lymphomas after solid organ transplantation: a collaborative transplant study report.	American journal of transplantation 	2004	79
15800326	3558	Dudley ME	Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma.	Journal of clinical oncology 	2005	443
19933795	3558	Hopkins S	SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.	Antimicrobial agents and chemotherapy	2010	41
21940902	3558	Bajaj JS	Linkage of gut microbiome with cognition in hepatic encephalopathy.	American journal of physiology. Gastrointestinal and liver physiology	2012	69
22710188	3558	Kennedy PTF	Preserved T-cell function in children and young adults with immune-tolerant chronic hepatitis B.	Gastroenterology	2012	39
23583734	3558	Hirschfield GM	The genetics of complex cholestatic disorders.	Gastroenterology	2013	28
25695689	3558	Zhang L	Tumor-infiltrating lymphocytes genetically engineered with an inducible gene encoding interleukin-12 for the immunotherapy of metastatic melanoma.	Clinical cancer research 	2015	29
25747273	3558	Lee JH	Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma.	Gastroenterology	2015	31
25850950	3558	Katz SC	Phase I Hepatic Immunotherapy for Metastases Study of Intra-Arterial Chimeric Antigen Receptor-Modified T-cell Therapy for CEA+ Liver Metastases.	Clinical cancer research 	2015	23
26444729	3558	Kappos L	Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis.	The New England journal of medicine	2015	26
27073224	3558	Koreth J	Efficacy, durability, and response predictors of low-dose interleukin-2 therapy for chronic graft-versus-host disease.	Blood	2016	15
2444978	3569	Gauldie J	Interferon beta 2/B-cell stimulatory factor type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cells.	Proceedings of the National Academy of Sciences of the United States of America	1987	261
12883485	3569	Kugelmas M	Cytokines and NASH: a pilot study of the effects of lifestyle modification and vitamin E.	Hepatology	2003	82
14567964	3569	Raper SE	Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer.	Molecular genetics and metabolism	2003	272
14960743	3569	Petersen KF	Impaired mitochondrial activity in the insulin-resistant offspring of patients with type 2 diabetes.	The New England journal of medicine	2004	463
15124018	3569	Nemeth E	IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin.	The Journal of clinical investigation	2004	452
15188351	3569	Nishimoto N	Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial.	Arthritis and rheumatism	2004	119
15886319	3569	Kemna E	Time-course analysis of hepcidin, serum iron, and plasma cytokine levels in humans injected with LPS.	Blood	2005	105
15942443	3569	Loguercio C	Beneficial effects of a probiotic VSL#3 on parameters of liver dysfunction in chronic liver diseases.	Journal of clinical gastroenterology	2005	87
16563942	3569	Petersen KF	Etiology of insulin resistance.	The American journal of medicine	2006	169
16613757	3569	Bastard JP	Recent advances in the relationship between obesity, inflammation, and insulin resistance.	European cytokine network	2006	383
17114290	3569	Petersen KF	Increased prevalence of insulin resistance and nonalcoholic fatty liver disease in Asian-Indian men.	Proceedings of the National Academy of Sciences of the United States of America	2006	82
17241887	3569	Isomoto H	Sustained IL-6/STAT-3 signaling in cholangiocarcinoma cells due to SOCS-3 epigenetic silencing.	Gastroenterology	2007	64
17716366	3569	Jeschke MG	Burn size determines the inflammatory and hypermetabolic response.	Critical care	2007	58
18627003	3569	van der Poorten D	Visceral fat: a key mediator of steatohepatitis in metabolic liver disease.	Hepatology	2008	78
18926322	3569	Martin SS	Leptin resistance: a possible interface of inflammation and metabolism in obesity-related cardiovascular disease.	Journal of the American College of Cardiology	2008	92
19137011	3569	Lin L	The STAT3 inhibitor NSC 74859 is effective in hepatocellular cancers with disrupted TGF-beta signaling.	Oncogene	2009	67
19267406	3569	Wong VW	High serum interleukin-6 level predicts future hepatocellular carcinoma development in patients with chronic hepatitis B.	International journal of cancer	2009	57
19318968	3569	Tarantino G	Could inflammatory markers help diagnose nonalcoholic steatohepatitis?	European journal of gastroenterology and hepatology	2009	46
19470923	3569	Zhu AX	Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study.	Journal of clinical oncology 	2009	136
19585655	3569	Marra F	Adipokines in liver diseases.	Hepatology	2009	93
19898853	3569	Knüpfer H	Serum interleukin-6 levels in colorectal cancer patients--a summary of published results.	International journal of colorectal disease	2010	56
19937696	3569	Hösel M	Not interferon, but interleukin-6 controls early gene expression in hepatitis B virus infection.	Hepatology	2009	72
20581244	3569	Wong VW	Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years.	Gut	2010	87
21042596	3569	Bertola A	Hepatic expression patterns of inflammatory and immune response genes associated with obesity and NASH in morbidly obese patients.	PloS one	2010	47
21726511	3569	Sandler NG	Host response to translocated microbial products predicts outcomes of patients with HBV or HCV infection.	Gastroenterology	2011	90
22334567	3569	Antoniades CG	Source and characterization of hepatic macrophages in acetaminophen-induced acute liver failure in humans.	Hepatology	2012	46
22821944	3569	Bajaj JS	Colonic mucosal microbiome differs from stool microbiome in cirrhosis and hepatic encephalopathy and is linked to cognition and inflammation.	American journal of physiology. Gastrointestinal and liver physiology	2012	72
23160966	3569	Piya MK	Adipokine inflammation and insulin resistance: the role of glucose, lipids and endotoxin.	The Journal of endocrinology	2013	37
23340215	3569	Singh AK	Metabolic syndrome and chronic kidney disease.	Current opinion in nephrology and hypertension	2013	27
23389848	3569	Yang X	MicroRNA-26a suppresses tumor growth and metastasis of human hepatocellular carcinoma by targeting interleukin-6-Stat3 pathway.	Hepatology	2013	66
23482247	3569	Basaranoglu M	Fructose as a key player in the development of fatty liver disease.	World journal of gastroenterology	2013	44
24618929	3569	Hartman J	Inflammation and atherosclerosis: a review of the role of interleukin-6 in the development of atherosclerosis and the potential for targeted drug therapy.	Cardiology in review	2014	31
24728071	3569	Miller CJ	Adjudicated morbidity and mortality outcomes by age among individuals with HIV infection on suppressive antiretroviral therapy.	PloS one	2014	22
24828436	3569	Bala S	Acute binge drinking increases serum endotoxin and bacterial DNA levels in healthy individuals.	PloS one	2014	38
24841946	3569	Lleo A	Shotgun proteomics: identification of unique protein profiles of apoptotic bodies from biliary epithelial cells.	Hepatology	2014	23
24910242	3569	Umemura A	Liver damage, inflammation, and enhanced tumorigenesis after persistent mTORC1 inhibition.	Cell metabolism	2014	22
24986424	3569	Wolf J	Interleukin-6 and its receptors: a highly regulated and dynamic system.	Cytokine	2014	43
25456364	3569	Kennedy GA	Addition of interleukin-6 inhibition with tocilizumab to standard graft-versus-host disease prophylaxis after allogeneic stem-cell transplantation: a phase 1/2 trial.	The Lancet. Oncology	2014	26
25731872	3569	Dubuquoy L	Progenitor cell expansion and impaired hepatocyte regeneration in explanted livers from alcoholic hepatitis.	Gut	2015	15
3056758	3630	Reaven GM	Banting lecture 1988. Role of insulin resistance in human disease.	Diabetes	1988	1192
3514343	3630	Nauck M	Reduced incretin effect in type 2 (non-insulin-dependent) diabetes.	Diabetologia	1986	177
8247074	3630	Lillioja S	Insulin resistance and insulin secretory dysfunction as precursors of non-insulin-dependent diabetes mellitus. Prospective studies of Pima Indians.	The New England journal of medicine	1993	204
10189543	3630	-	The Diabetes Prevention Program. Design and methods for a clinical trial in the prevention of type 2 diabetes.	Diabetes care	1999	180
10209084	3630	Andrews RC	Glucocorticoids and insulin resistance: old hormones, new targets.	Clinical science	1999	100
10454950	3630	DeFronzo RA	Pharmacologic therapy for type 2 diabetes mellitus.	Annals of internal medicine	1999	109
11289033	3630	Ryan EA	Clinical outcomes and insulin secretion after islet transplantation with the Edmonton protocol.	Diabetes	2001	90
11742415	3630	Moller DE	New drug targets for type 2 diabetes and the metabolic syndrome.	Nature	2001	107
11826410	3630	Pagano G	Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: further evidence for an etiologic association.	Hepatology	2002	105
11872682	3630	Mayerson AB	The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes.	Diabetes	2002	98
12367816	3630	Barker DJ	Fetal programming of coronary heart disease.	Trends in endocrinology and metabolism	2002	122
12399260	3630	Elliott SS	Fructose, weight gain, and the insulin resistance syndrome.	The American journal of clinical nutrition	2002	170
12668987	3630	Marchesini G	Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome.	Hepatology	2003	435
12717402	3630	Neuschwander-Tetri BA	Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference.	Hepatology	2003	351
12750520	3630	Petersen KF	Mitochondrial dysfunction in the elderly: possible role in insulin resistance.	Science	2003	450
12829641	3630	Basu R	Mechanisms of the age-associated deterioration in glucose tolerance: contribution of alterations in insulin secretion, action, and clearance.	Diabetes	2003	84
14693724	3630	Palmer JP	C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve beta-cell function: report of an ADA workshop, 21-22 October 2001.	Diabetes	2004	112
14752837	3630	Promrat K	A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis.	Hepatology	2004	112
15294056	3630	Storlien L	Metabolic flexibility.	The Proceedings of the Nutrition Society	2004	71
15662003	3630	Rhodes CJ	Type 2 diabetes-a matter of beta-cell life and death?	Science	2005	195
15669880	3630	Krentz AJ	Oral antidiabetic agents: current role in type 2 diabetes mellitus.	Drugs	2005	126
15723702	3630	Basciano H	Fructose, insulin resistance, and metabolic dyslipidemia.	Nutrition and metabolism	2005	129
15734833	3630	Petersen KF	Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes.	Diabetes	2005	183
15747110	3630	Bugianesi E	Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms.	Diabetologia	2005	109
15842582	3630	Bugianesi E	A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease.	The American journal of gastroenterology	2005	107
15951550	3630	Fartoux L	Insulin resistance is a cause of steatosis and fibrosis progression in chronic hepatitis C.	Gut	2005	73
16250043	3630	Bugianesi E	Insulin resistance: a metabolic pathway to chronic liver disease.	Hepatology	2005	115
16456680	3630	Yki-Järvinen H	Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study.	Diabetologia	2006	83
16968800	3630	Utzschneider KM	Review: The role of insulin resistance in nonalcoholic fatty liver disease.	The Journal of clinical endocrinology and metabolism	2006	97
17130651	3630	Morino K	Molecular mechanisms of insulin resistance in humans and their potential links with mitochondrial dysfunction.	Diabetes	2006	192
17158419	3630	Lê KA	A 4-wk high-fructose diet alters lipid metabolism without affecting insulin sensitivity or ectopic lipids in healthy humans.	The American journal of clinical nutrition	2006	76
17261637	3630	Gromada J	Alpha-cells of the endocrine pancreas: 35 years of research but the enigma remains.	Endocrine reviews	2007	149
17341552	3630	Cobelli C	Assessment of beta-cell function in humans, simultaneously with insulin sensitivity and hepatic extraction, from intravenous and oral glucose tests.	American journal of physiology. Endocrinology and metabolism	2007	75
17567459	3630	Pessayre D	Role of mitochondria in non-alcoholic fatty liver disease.	Journal of gastroenterology and hepatology	2007	59
17684197	3630	Zivkovic AM	Comparative review of diets for the metabolic syndrome: implications for nonalcoholic fatty liver disease.	The American journal of clinical nutrition	2007	75
17728149	3630	Adams LA	Nonalcoholic fatty liver disease.	Annals of epidemiology	2007	66
17875176	3630	Ferrante AW Jr	Obesity-induced inflammation: a metabolic dialogue in the language of inflammation.	Journal of internal medicine	2007	111
17981116	3630	Pospisilik JA	Targeted deletion of AIF decreases mitochondrial oxidative phosphorylation and protects from obesity and diabetes.	Cell	2007	143
18434349	3630	Macfarlane DP	Glucocorticoids and fatty acid metabolism in humans: fuelling fat redistribution in the metabolic syndrome.	The Journal of endocrinology	2008	64
18471547	3630	Torres DM	Diagnosis and therapy of nonalcoholic steatohepatitis.	Gastroenterology	2008	69
18474251	3630	Kotronen A	Increased liver fat, impaired insulin clearance, and hepatic and adipose tissue insulin resistance in type 2 diabetes.	Gastroenterology	2008	52
18769702	3630	Vos MB	Dietary fructose consumption among US children and adults: the Third National Health and Nutrition Examination Survey.	Medscape journal of medicine	2008	90
19223251	3630	Petta S	Non-alcoholic fatty liver disease pathogenesis: the present and the future.	Digestive and liver disease 	2009	48
19318219	3630	Geer EB	Gender differences in insulin resistance, body composition, and energy balance.	Gender medicine	2009	107
19332493	3630	Brøns C	Impact of short-term high-fat feeding on glucose and insulin metabolism in young healthy men.	The Journal of physiology	2009	50
19358089	3630	Blüher M	Adipose tissue dysfunction in obesity.	Experimental and clinical endocrinology and diabetes 	2009	101
19365105	3630	Zeyda M	Obesity, inflammation, and insulin resistance--a mini-review.	Gerontology	2009	67
19444870	3630	St George A	Independent effects of physical activity in patients with nonalcoholic fatty liver disease.	Hepatology	2009	45
19637289	3630	Johnson NA	Aerobic exercise training reduces hepatic and visceral lipids in obese individuals without weight loss.	Hepatology	2009	88
19940134	3630	Alkhouri N	Adipocyte apoptosis, a link between obesity, insulin resistance, and hepatic steatosis.	The Journal of biological chemistry	2010	82
20022465	3630	Das UN	Obesity: genes, brain, gut, and environment.	Nutrition	2010	45
20079586	3630	Wulan SN	Ethnic differences in body composition and the associated metabolic profile: a comparative study between Asians and Caucasians.	Maturitas	2010	40
20086073	3630	Tappy L	Metabolic effects of fructose and the worldwide increase in obesity.	Physiological reviews	2010	188
20361178	3630	DeFronzo RA	Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009.	Diabetologia	2010	131
20480025	3630	Hanhineva K	Impact of dietary polyphenols on carbohydrate metabolism.	International journal of molecular sciences	2010	69
20522594	3630	Kars M	Tauroursodeoxycholic Acid may improve liver and muscle but not adipose tissue insulin sensitivity in obese men and women.	Diabetes	2010	93
20798346	3630	Unger RH	Paracrinology of islets and the paracrinopathy of diabetes.	Proceedings of the National Academy of Sciences of the United States of America	2010	67
20870709	3630	Huang-Doran I	Lipodystrophy: metabolic insights from a rare disorder.	The Journal of endocrinology	2010	49
20978091	3630	Schauer IE	Insulin resistance, defective insulin-mediated fatty acid suppression, and coronary artery calcification in subjects with and without type 1 diabetes: The CACTI study.	Diabetes	2011	48
21216854	3630	Schmid AI	Liver ATP synthesis is lower and relates to insulin sensitivity in patients with type 2 diabetes.	Diabetes care	2011	36
21245030	3630	Hooper AJ	Genetic determinants of hepatic steatosis in man.	Journal of lipid research	2011	42
21350183	3630	Chiang DJ	Obesity, diabetes mellitus, and liver fibrosis.	American journal of physiology. Gastrointestinal and liver physiology	2011	39
21536711	3630	Semple RK	Genetic syndromes of severe insulin resistance.	Endocrine reviews	2011	40
21599535	3630	Leavens KF	Insulin signaling to hepatic lipid metabolism in health and disease.	Critical reviews in biochemistry and molecular biology	2011	37
21614570	3630	Camastra S	Early and longer term effects of gastric bypass surgery on tissue-specific insulin sensitivity and beta cell function in morbidly obese patients with and without type 2 diabetes.	Diabetologia	2011	37
21700865	3630	Cohen JC	Human fatty liver disease: old questions and new insights.	Science	2011	429
21718726	3630	Dongiovanni P	Iron in fatty liver and in the metabolic syndrome: a promising therapeutic target.	Journal of hepatology	2011	59
21912398	3630	Szendroedi J	The role of mitochondria in insulin resistance and type 2 diabetes mellitus.	Nature reviews. Endocrinology	2011	92
21930939	3630	Kumashiro N	Cellular mechanism of insulin resistance in nonalcoholic fatty liver disease.	Proceedings of the National Academy of Sciences of the United States of America	2011	104
22194737	3630	Mazza A	The role of metformin in the management of NAFLD.	Experimental diabetes research	2012	32
22326434	3630	Cusi K	Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications.	Gastroenterology	2012	112
22355097	3630	Dowling RJ	Metformin in cancer: translational challenges.	Journal of molecular endocrinology	2012	75
22425588	3630	Magkos F	Intrahepatic diacylglycerol content is associated with hepatic insulin resistance in obese subjects.	Gastroenterology	2012	34
22560210	3630	Jornayvaz FR	Diacylglycerol activation of protein kinase Cε and hepatic insulin resistance.	Cell metabolism	2012	65
22719752	3630	Hsieh MC	The influence of type 2 diabetes and glucose-lowering therapies on cancer risk in the Taiwanese.	Experimental diabetes research	2012	39
22722431	3630	Milić S	Nonalcoholic fatty liver disease/steatohepatitis: epidemiology, pathogenesis, clinical presentation and treatment.	Digestive diseases	2012	47
22741595	3630	Liu CJ	Prevalence and risk factors for non-alcoholic fatty liver disease in Asian people who are not obese.	Journal of gastroenterology and hepatology	2012	34
23107255	3630	Müller MJ	Beyond the body mass index: tracking body composition in the pathogenesis of obesity and the metabolic syndrome.	Obesity reviews 	2012	32
23363012	3630	Masuoka HC	Nonalcoholic fatty liver disease: an emerging threat to obese and diabetic individuals.	Annals of the New York Academy of Sciences	2013	44
23381014	3630	Singh S	Anti-diabetic medications and the risk of hepatocellular cancer: a systematic review and meta-analysis.	The American journal of gastroenterology	2013	48
23458891	3630	Farrell GC	NAFLD in Asia--as common and important as in the West.	Nature reviews. Gastroenterology and hepatology	2013	69
23703888	3630	Lazo M	Prevalence of nonalcoholic fatty liver disease in the United States: the Third National Health and Nutrition Examination Survey, 1988-1994.	American journal of epidemiology	2013	112
23863826	3630	Misra A	Obesity and dyslipidemia in South Asians.	Nutrients	2013	32
23929732	3630	Birkenfeld AL	Nonalcoholic fatty liver disease, hepatic insulin resistance, and type 2 diabetes.	Hepatology	2014	70
24215793	3630	Mezza T	Insulin resistance alters islet morphology in nondiabetic humans.	Diabetes	2014	27
24241533	3630	Bojsen-Møller KN	Early enhancements of hepatic and later of peripheral insulin sensitivity combined with increased postprandial insulin secretion contribute to improved glycemic control after Roux-en-Y gastric bypass.	Diabetes	2014	25
24256086	3630	Nobili V	Obstructive sleep apnea syndrome affects liver histology and inflammatory cell activation in pediatric nonalcoholic fatty liver disease, regardless of obesity/insulin resistance.	American journal of respiratory and critical care medicine	2014	20
24651807	3630	Cobelli C	The oral minimal model method.	Diabetes	2014	24
24899308	3630	Perry RJ	The role of hepatic lipids in hepatic insulin resistance and type 2 diabetes.	Nature	2014	100
25035342	3630	Lim S	Links between ectopic fat and vascular disease in humans.	Arteriosclerosis, thrombosis, and vascular biology	2014	24
25825943	3630	Schwarz JM	Effect of a High-Fructose Weight-Maintaining Diet on Lipogenesis and Liver Fat.	The Journal of clinical endocrinology and metabolism	2015	20
26319013	3630	Negro F	Extrahepatic morbidity and mortality of chronic hepatitis C.	Gastroenterology	2015	19
14578911	3845	Lamarre D	An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus.	Nature	2003	147
14966562	3845	Chan IT	Conditional expression of oncogenic K-ras from its endogenous promoter induces a myeloproliferative disease.	The Journal of clinical investigation	2004	104
17512720	3845	Duffy MJ	Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use.	European journal of cancer	2007	83
19056857	3845	Santini D	High concordance of KRAS status between primary colorectal tumors and related metastatic sites: implications for clinical practice.	The oncologist	2008	57
19270292	3845	Balsitis SJ	Tropism of dengue virus in mice and humans defined by viral nonstructural protein 3-specific immunostaining.	The American journal of tropical medicine and hygiene	2009	83
19372139	3845	Tsang WP	The miR-18a* microRNA functions as a potential tumor suppressor by targeting on K-Ras.	Carcinogenesis	2009	58
19595305	3845	Young A	Ras signaling and therapies.	Advances in cancer research	2009	79
21228335	3845	Bokemeyer C	Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study.	Annals of oncology 	2011	163
21239505	3845	Tie J	KRAS mutation is associated with lung metastasis in patients with curatively resected colorectal cancer.	Clinical cancer research 	2011	47
21364579	3845	Knijn N	KRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients.	British journal of cancer	2011	63
22266220	3845	O'Dell MR	Kras(G12D) and p53 mutation cause primary intrahepatic cholangiocarcinoma.	Cancer research	2012	33
22869577	3845	McPhee F	Preclinical Profile and Characterization of the Hepatitis C Virus NS3 Protease Inhibitor Asunaprevir (BMS-650032).	Antimicrobial agents and chemotherapy	2012	35
23200175	3845	Jänne PA	Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.	The Lancet. Oncology	2013	153
23295441	3845	Sia D	Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes.	Gastroenterology	2013	61
23426905	3845	Shiraha H	Human hepatocyte carcinogenesis (review).	International journal of oncology	2013	30
23510984	3845	Cohn AL	A randomized, placebo-controlled phase 2 study of ganitumab or conatumumab in combination with FOLFIRI for second-line treatment of mutant KRAS metastatic colorectal cancer.	Annals of oncology 	2013	27
23569301	3845	Ye LC	Randomized controlled trial of cetuximab plus chemotherapy for patients with KRAS wild-type unresectable colorectal liver-limited metastases.	Journal of clinical oncology 	2013	47
24018645	3845	Vauthey JN	RAS mutation status predicts survival and patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases.	Annals of surgery	2013	29
25385103	3845	Ottosen S	In vitro antiviral activity and preclinical and clinical resistance profile of miravirsen, a novel anti-hepatitis C virus therapeutic targeting the human factor miR-122.	Antimicrobial agents and chemotherapy	2015	23
25706875	3845	Matano M	Modeling colorectal cancer using CRISPR-Cas9-mediated engineering of human intestinal organoids.	Nature medicine	2015	74
25909356	3845	Zeuzem S	Grazoprevir-Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection: A Randomized Trial.	Annals of internal medicine	2015	64
26608120	3845	Johnson DB	Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms.	European journal of cancer	2015	18
21039302	3875	Musso G	Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity.	Annals of medicine	2011	182
21145805	3875	Tamimi TI	An apoptosis panel for nonalcoholic steatohepatitis diagnosis.	Journal of hepatology	2011	38
21875310	3875	Smith BW	Non-alcoholic fatty liver disease.	Critical reviews in clinical laboratory sciences	2011	56
21993925	3875	Joka D	Prospective biopsy-controlled evaluation of cell death biomarkers for prediction of liver fibrosis and nonalcoholic steatohepatitis.	Hepatology	2012	38
23278163	3875	Festi D	Review article: the diagnosis of non-alcoholic fatty liver disease -- availability and accuracy of non-invasive methods.	Alimentary pharmacology and therapeutics	2013	36
23973932	3875	Cusi K	Limited value of plasma cytokeratin-18 as a biomarker for NASH and fibrosis in patients with non-alcoholic fatty liver disease.	Journal of hepatology	2014	38
24061203	3875	Castera L	Noninvasive evaluation of NAFLD.	Nature reviews. Gastroenterology and hepatology	2013	42
24308774	3875	Kwok R	Systematic review with meta-analysis: non-invasive assessment of non-alcoholic fatty liver disease--the role of transient elastography and plasma cytokeratin-18 fragments.	Alimentary pharmacology and therapeutics	2014	32
25703085	3875	Francque S	PPARα gene expression correlates with severity and histological treatment response in patients with non-alcoholic steatohepatitis.	Journal of hepatology	2015	19
26677985	3875	Imajo K	Magnetic Resonance Imaging More Accurately Classifies Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease Than Transient Elastography.	Gastroenterology	2016	12
12387968	4051	Nebert DW	Clinical importance of the cytochromes P450.	Lancet	2002	170
15660968	4051	Schachter M	Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update.	Fundamental and clinical pharmacology	2005	101
18218849	4051	Morgan ET	Regulation of drug-metabolizing enzymes and transporters in infection, inflammation, and cancer.	Drug metabolism and disposition	2008	58
18724832	4051	Chang TT	Monolayer and spheroid culture of human liver hepatocellular carcinoma cell line cells demonstrate distinct global gene expression patterns and functional phenotypes.	Tissue engineering. Part A	2009	53
21948869	4051	Wetmore BA	Integration of dosimetry, exposure, and high-throughput screening data in chemical toxicity assessment.	Toxicological sciences 	2012	37
9500542	5205	Bull LN	A gene encoding a P-type ATPase mutated in two forms of hereditary cholestasis.	Nature genetics	1998	114
17948906	5205	Paulusma CC	ATP8B1 requires an accessory protein for endoplasmic reticulum exit and plasma membrane lipid flippase activity.	Hepatology	2008	69
10536005	5265	Morral N	Administration of helper-dependent adenoviral vectors and sequential delivery of different vector serotype for long-term liver-directed gene transfer in baboons.	Proceedings of the National Academy of Sciences of the United States of America	1999	98
15978931	5265	Stoller JK	Alpha1-antitrypsin deficiency.	Lancet	2005	81
16183649	5265	Hidvegi T	Accumulation of mutant alpha1-antitrypsin Z in the endoplasmic reticulum activates caspases-4 and -12, NFkappaB, and BAP31 but not the unfolded protein response.	The Journal of biological chemistry	2005	66
20522742	5265	Hidvegi T	An autophagy-enhancing drug promotes degradation of mutant alpha1-antitrypsin Z and reduces hepatic fibrosis.	Science	2010	157
21960536	5265	Stoller JK	A review of α1-antitrypsin deficiency.	American journal of respiratory and critical care medicine	2012	43
21993621	5265	Yusa K	Targeted gene correction of α1-antitrypsin deficiency in induced pluripotent stem cells.	Nature	2011	170
23325555	5265	Choi SM	Efficient drug screening and gene correction for treating liver disease using patient-specific stem cells.	Hepatology	2013	51
9748221	5465	Chinetti G	Activation of proliferator-activated receptors alpha and gamma induces apoptosis of human monocyte-derived macrophages.	The Journal of biological chemistry	1998	152
16447287	5465	Farrell GC	Nonalcoholic fatty liver disease: from steatosis to cirrhosis.	Hepatology	2006	470
16511589	5465	Lefebvre P	Sorting out the roles of PPAR alpha in energy metabolism and vascular homeostasis.	The Journal of clinical investigation	2006	178
16511590	5465	Semple RK	PPAR gamma and human metabolic disease.	The Journal of clinical investigation	2006	170
20346437	5465	Zhong H	Integrating pathway analysis and genetics of gene expression for genome-wide association studies.	American journal of human genetics	2010	124
21183072	5465	Carone BR	Paternally induced transgenerational environmental reprogramming of metabolic gene expression in mammals.	Cell	2010	215
21397692	5465	White SS	Endocrine disrupting properties of perfluorooctanoic acid.	The Journal of steroid biochemistry and molecular biology	2011	37
22056763	5465	Tailleux A	Roles of PPARs in NAFLD: potential therapeutic targets.	Biochimica et biophysica acta	2012	46
23150796	6554	Yan H	Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus.	eLife	2012	252
24317697	6554	Zhou X	Structural basis of the alternating-access mechanism in a bile acid transporter.	Nature	2014	21
24390325	6554	Yan H	Viral entry of hepatitis B and D viruses and bile salts transportation share common molecular determinants on sodium taurocholate cotransporting polypeptide.	Journal of virology	2014	30
24867799	6554	Vaz FM	Sodium taurocholate cotransporting polypeptide (SLC10A1) deficiency: conjugated hypercholanemia without a clear clinical phenotype.	Hepatology	2015	23
17103105	6868	Marelli L	Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies.	Cardiovascular and interventional radiology	2007	129
17239480	6868	Varela M	Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics.	Journal of hepatology	2007	142
21816126	6868	Sangro B	Radioembolization for hepatocellular carcinoma.	Journal of hepatology	2012	59
22314428	6868	Burrel M	Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using Drug Eluting Beads. Implications for clinical practice and trial design.	Journal of hepatology	2012	66
23269991	6868	Peng ZW	Radiofrequency ablation with or without transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma: a prospective randomized trial.	Journal of clinical oncology 	2013	56
24559042	6868	Xiao WK	Prognostic significance of neutrophil-lymphocyte ratio in hepatocellular carcinoma: a meta-analysis.	BMC cancer	2014	36
24930619	6868	Ricke J	Safety and toxicity of radioembolization plus Sorafenib in advanced hepatocellular carcinoma: analysis of the European multicentre trial SORAMIC.	Liver international 	2015	16
24937669	6868	Golfieri R	Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma.	British journal of cancer	2014	30
26809111	6868	Lencioni R	Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial.	Journal of hepatology	2016	42
10573511	7018	Angulo P	Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis.	Hepatology	1999	224
19484405	7018	Anderson GJ	Mammalian iron transport.	Cellular and molecular life sciences 	2009	52
20080552	7018	Choi CH	Mechanism of active targeting in solid tumors with transferrin-containing gold nanoparticles.	Proceedings of the National Academy of Sciences of the United States of America	2010	133
21855608	7018	Brissot P	Non-transferrin bound iron: a key role in iron overload and iron toxicity.	Biochimica et biophysica acta	2012	71
22843282	7276	Coelho T	Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial.	Neurology	2012	89
23425518	7276	Ando Y	Guideline of transthyretin-related hereditary amyloidosis for clinicians.	Orphanet journal of rare diseases	2013	36
26308415	7276	Ericzon BG	Liver Transplantation for Hereditary Transthyretin Amyloidosis: After 20 Years Still the Best Therapeutic Alternative?	Transplantation	2015	24
9806540	8647	Strautnieks SS	A gene encoding a liver-specific ABC transporter is mutated in progressive familial intrahepatic cholestasis.	Nature genetics	1998	136
18395098	8647	Strautnieks SS	Severe bile salt export pump deficiency: 82 different ABCB11 mutations in 109 families.	Gastroenterology	2008	59
21965623	8647	Dawson S	In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.	Drug metabolism and disposition	2012	37
24799086	8647	Aleo MD	Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.	Hepatology	2014	21
12611609	9370	Díez JJ	The role of the novel adipocyte-derived hormone adiponectin in human disease.	European journal of endocrinology	2003	150
12829629	9370	Iwaki M	Induction of adiponectin, a fat-derived antidiabetic and antiatherogenic factor, by nuclear receptors.	Diabetes	2003	133
14699128	9370	Pajvani UB	Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity.	The Journal of biological chemistry	2004	226
15369797	9370	Wolf AM	Adiponectin induces the anti-inflammatory cytokines IL-10 and IL-1RA in human leukocytes.	Biochemical and biophysical research communications	2004	133
17495599	9370	Lara-Castro C	Adiponectin and the metabolic syndrome: mechanisms mediating risk for metabolic and cardiovascular disease.	Current opinion in lipidology	2007	61
18503774	9370	Ratziu V	Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial.	Gastroenterology	2008	97
21040935	9370	Polyzos SA	Serum total adiponectin in nonalcoholic fatty liver disease: a systematic review and meta-analysis.	Metabolism	2011	38
21734787	9370	Buechler C	Adiponectin, a key adipokine in obesity related liver diseases.	World journal of gastroenterology	2011	50
22508243	9370	Savard C	Synergistic interaction of dietary cholesterol and dietary fat in inducing experimental steatohepatitis.	Hepatology	2013	45
22561530	9370	Hoyos CM	Cardiometabolic changes after continuous positive airway pressure for obstructive sleep apnoea: a randomised sham-controlled study.	Thorax	2012	30
23781214	9370	Kwon H	Adipokines mediate inflammation and insulin resistance.	Frontiers in endocrinology	2013	62
10858438	10062	Costet P	Sterol-dependent transactivation of the ABC1 promoter by the liver X receptor/retinoid X receptor.	The Journal of biological chemistry	2000	155
11035776	10062	Venkateswaran A	Control of cellular cholesterol efflux by the nuclear oxysterol receptor LXR alpha.	Proceedings of the National Academy of Sciences of the United States of America	2000	188
12690094	10062	Tontonoz P	Liver X receptor signaling pathways in cardiovascular disease.	Molecular endocrinology	2003	137
17936707	10062	Li X	SIRT1 deacetylates and positively regulates the nuclear receptor LXR.	Molecular cell	2007	197
21350215	10062	Chinetti-Gbaguidi G	Human atherosclerotic plaque alternative macrophages display low cholesterol handling but high phagocytosis because of distinct activities of the PPARγ and LXRα pathways.	Circulation research	2011	72
22154776	10062	Finn AV	Hemoglobin directs macrophage differentiation and prevents foam cell formation in human atherosclerotic plaques.	Journal of the American College of Cardiology	2012	46
22347525	10062	Lee JS	Pharmacological ER stress promotes hepatic lipogenesis and lipid droplet formation.	American journal of translational research	2012	32
23206728	10062	Musso G	Cholesterol metabolism and the pathogenesis of non-alcoholic steatohepatitis.	Progress in lipid research	2013	41
15830281	10178	Llovet JM	Updated treatment approach to hepatocellular carcinoma.	Journal of gastroenterology	2005	121
21523730	10178	Farges O	AJCC 7th edition of TNM staging accurately discriminates outcomes of patients with resectable intrahepatic cholangiocarcinoma: By the AFC-IHCC-2009 study group.	Cancer	2011	41
15670660	10327	Lieber CS	Alcoholic fatty liver: its pathogenesis and mechanism of progression to inflammation and fibrosis.	Alcohol	2004	129
19168210	10327	Schuckit MA	Alcohol-use disorders.	Lancet	2009	80
17979893	10395	Durkin ME	DLC-1:a Rho GTPase-activating protein and tumour suppressor.	Journal of cellular and molecular medicine	2007	65
16814713	10413	Zender L	Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach.	Cell	2006	374
17437995	10413	Pan D	Hippo signaling in organ size control.	Genes and development	2007	204
17889654	10413	Dong J	Elucidation of a universal size-control mechanism in Drosophila and mammals.	Cell	2007	582
17974916	10413	Zhao B	Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control.	Genes and development	2007	583
17980593	10413	Camargo FD	YAP1 increases organ size and expands undifferentiated progenitor cells.	Current biology 	2007	317
19551889	10413	Xu MZ	Yes-associated protein is an independent prognostic marker in hepatocellular carcinoma.	Cancer	2009	124
19878874	10413	Zhou D	Mst1 and Mst2 maintain hepatocyte quiescence and suppress hepatocellular carcinoma development through inactivation of the Yap1 oncogene.	Cancer cell	2009	261
20226166	10413	Liu AM	MicroRNA-375 targets Hippo-signaling effector YAP in liver cancer and inhibits tumor properties.	Biochemical and biophysical research communications	2010	64
21076472	10413	Xu MZ	AXL receptor kinase is a mediator of YAP-dependent oncogenic functions in hepatocellular carcinoma.	Oncogene	2011	46
21102585	10413	Avruch J	Mst1/2 signalling to Yap: gatekeeper for liver size and tumour development.	British journal of cancer	2011	41
22337891	10413	Konsavage WM Jr	Wnt/β-catenin signaling regulates Yes-associated protein (YAP) gene expression in colorectal carcinoma cells.	The Journal of biological chemistry	2012	62
22609549	10413	Straßburger K	Insulin/IGF signaling drives cell proliferation in part via Yorkie/YAP.	Developmental biology	2012	32
22677547	10413	Liu-Chittenden Y	Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP.	Genes and development	2012	210
22707013	10413	Zhang T	Hepatitis B virus X protein modulates oncogene Yes-associated protein by CREB to promote growth of hepatoma cells.	Hepatology	2012	42
22886419	10413	Bai H	Yes-associated protein regulates the hepatic response after bile duct ligation.	Hepatology	2012	32
23143395	10413	Tumaneng K	YAP mediates crosstalk between the Hippo and PI(3)K–TOR pathways by suppressing PTEN via miR-29.	Nature cell biology	2012	87
23419361	10413	Tschaharganeh DF	Yes-associated protein up-regulates Jagged-1 and activates the Notch pathway in human hepatocellular carcinoma.	Gastroenterology	2013	57
23542177	10413	Mao B	SIRT1 regulates YAP2-mediated cell proliferation and chemoresistance in hepatocellular carcinoma.	Oncogene	2014	24
24268772	10413	Anakk S	Bile acids activate YAP to promote liver carcinogenesis.	Cell reports	2013	25
24323901	10413	Touil Y	Colon cancer cells escape 5FU chemotherapy-induced cell death by entering stemness and quiescence associated with the c-Yes/YAP axis.	Clinical cancer research 	2014	32
24468535	10413	Wang J	Mutual inhibition between YAP and SRSF1 maintains long non-coding RNA, Malat1-induced tumourigenesis in liver cancer.	Cellular signalling	2014	21
24884509	10413	Tu K	Fbxw7 is an independent prognostic marker and induces apoptosis and growth arrest by regulating YAP abundance in hepatocellular carcinoma.	Molecular cancer	2014	25
25010260	10413	Perra A	YAP activation is an early event and a potential therapeutic target in liver cancer development.	Journal of hepatology	2014	40
25293527	10413	Yu FX	Hippo pathway regulation of gastrointestinal tissues.	Annual review of physiology	2015	15
25772357	10413	Fitamant J	YAP Inhibition Restores Hepatocyte Differentiation in Advanced HCC, Leading to Tumor Regression.	Cell reports	2015	26
25908270	10413	Mannaerts I	The Hippo pathway effector YAP controls mouse hepatic stellate cell activation.	Journal of hepatology	2015	22
26109051	10413	Chen Q	Homeostatic control of Hippo signaling activity revealed by an endogenous activating mutation in YAP.	Genes and development	2015	23
14699511	10599	Kullak-Ublick GA	Enterohepatic bile salt transporters in normal physiology and liver disease.	Gastroenterology	2004	85
16697742	10599	Ho RH	Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics.	Gastroenterology	2006	91
17108811	10599	Pasanen MK	SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid.	Pharmacogenetics and genomics	2006	79
18650507	10599	SEARCH Collaborative Group.	SLCO1B1 variants and statin-induced myopathy--a genomewide study.	The New England journal of medicine	2008	353
19785645	10599	Kalliokoski A	Impact of OATP transporters on pharmacokinetics.	British journal of pharmacology	2009	113
20501720	10599	Tsuboyama T	Hepatocellular carcinoma: hepatocyte-selective enhancement at gadoxetic acid-enhanced MR imaging--correlation with expression of sinusoidal and canalicular transporters and bile accumulation.	Radiology	2010	49
21245207	10599	Niemi M	Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake.	Pharmacological reviews	2011	88
22232210	10599	van de Steeg E	Complete OATP1B1 and OATP1B3 deficiency causes human Rotor syndrome by interrupting conjugated bilirubin reuptake into the liver.	The Journal of clinical investigation	2012	42
24122874	10599	Prasad B	Interindividual variability in hepatic organic anion-transporting polypeptides and P-glycoprotein (ABCB1) protein expression: quantification by liquid chromatography tandem mass spectroscopy and influence of genotype, age, and sex.	Drug metabolism and disposition	2014	32
14744933	10891	Fan M	Suppression of mitochondrial respiration through recruitment of p160 myb binding protein to PGC-1alpha: modulation by p38 MAPK.	Genes and development	2004	86
17704301	10891	Westerbacka J	Genes involved in fatty acid partitioning and binding, lipolysis, monocyte/macrophage recruitment, and inflammation are overexpressed in the human fatty liver of insulin-resistant subjects.	Diabetes	2007	79
18680712	10891	Li S	Genome-wide coactivation analysis of PGC-1alpha identifies BAF60a as a regulator of hepatic lipid metabolism.	Cell metabolism	2008	60
19342452	10891	Thorn SR	Intrauterine growth restriction increases fetal hepatic gluconeogenic capacity and reduces messenger ribonucleic acid translation initiation and nutrient sensing in fetal liver and skeletal muscle.	Endocrinology	2009	48
19542216	10891	Wareski P	PGC-1{alpha} and PGC-1{beta} regulate mitochondrial density in neurons.	The Journal of biological chemistry	2009	78
19853062	10891	Spindler SR	Caloric restriction: from soup to nuts.	Ageing research reviews	2010	58
20890895	10891	Sookoian S	Epigenetic regulation of insulin resistance in nonalcoholic fatty liver disease: impact of liver methylation of the peroxisome proliferator-activated receptor γ coactivator 1α promoter.	Hepatology	2010	44
22055504	10891	Timmers S	Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans.	Cell metabolism	2011	217
22318941	10891	Wang B	Stat3-mediated activation of microRNA-23a suppresses gluconeogenesis in hepatocellular carcinoma by down-regulating glucose-6-phosphatase and peroxisome proliferator-activated receptor gamma, coactivator 1 alpha.	Hepatology	2012	54
24411942	10891	Roberts LD	β-Aminoisobutyric acid induces browning of white fat and hepatic β-oxidation and is inversely correlated with cardiometabolic risk factors.	Cell metabolism	2014	64
24722248	10891	Kurtz CL	MicroRNA-29 fine-tunes the expression of key FOXA2-activated lipid metabolism genes and is dysregulated in animal models of insulin resistance and diabetes.	Diabetes	2014	24
25516156	10891	Blednov YA	Peroxisome proliferator-activated receptors α and γ are linked with alcohol consumption in mice and withdrawal and dependence in humans.	Alcoholism, clinical and experimental research	2015	19
20609352	11156	Wang H	PCBP1 suppresses the translation of metastasis-associated PRL-3 phosphatase.	Cancer cell	2010	45
15205477	23411	Cohen HY	Calorie restriction promotes mammalian cell survival by inducing the SIRT1 deacetylase.	Science	2004	531
16335928	23411	Napper AD	Discovery of indoles as potent and selective inhibitors of the deacetylase SIRT1.	Journal of medicinal chemistry	2005	91
18239056	23411	You M	Involvement of mammalian sirtuin 1 in the action of ethanol in the liver.	American journal of physiology. Gastrointestinal and liver physiology	2008	75
18662546	23411	Asher G	SIRT1 regulates circadian clock gene expression through PER2 deacetylation.	Cell	2008	332
21345154	23411	Schug TT	Sirtuin 1 in lipid metabolism and obesity.	Annals of medicine	2011	66
21527554	23411	Chen J	Sirtuin 1 is upregulated in a subset of hepatocellular carcinomas where it is essential for telomere maintenance and tumor cell growth.	Cancer research	2011	41
22045767	23411	Engels EA	Spectrum of cancer risk among US solid organ transplant recipients.	JAMA	2011	143
22146883	23411	Chen HC	SIRT1 promotes tumorigenesis and resistance to chemotherapy in hepatocellular carcinoma and its expression predicts poor prognosis.	Annals of surgical oncology	2012	37
22553202	23411	Nin V	Role of deleted in breast cancer 1 (DBC1) protein in SIRT1 deacetylase activation induced by protein kinase A and AMP-activated protein kinase.	The Journal of biological chemistry	2012	38
22728651	23411	Lee CW	AMPK promotes p53 acetylation via phosphorylation and inactivation of SIRT1 in liver cancer cells.	Cancer research	2012	50
22902550	23411	Castro RE	miR-34a/SIRT1/p53 is suppressed by ursodeoxycholic acid in the rat liver and activated by disease severity in human non-alcoholic fatty liver disease.	Journal of hepatology	2013	54
23257294	23411	Li X	SIRT1 and energy metabolism.	Acta biochimica et biophysica Sinica	2013	36
23696823	23411	Endo H	Butyrate-producing probiotics reduce nonalcoholic fatty liver disease progression in rats: new insight into the probiotics for the gut-liver axis.	PloS one	2013	33
23728341	23411	Bae HJ	MicroRNA-29c functions as a tumor suppressor by direct targeting oncogenic SIRT1 in hepatocellular carcinoma.	Oncogene	2014	36
24133372	23411	Yuan H	The emerging and diverse roles of sirtuins in cancer: a clinical perspective.	OncoTargets and therapy	2013	47
24184811	23411	Li Y	Hepatic SIRT1 attenuates hepatic steatosis and controls energy balance in mice by inducing fibroblast growth factor 21.	Gastroenterology	2014	33
24314860	23411	Wang S	Novel insights of dietary polyphenols and obesity.	The Journal of nutritional biochemistry	2014	66
25445538	23411	Szkudelski T	Resveratrol and diabetes: from animal to human studies.	Biochimica et biophysica acta	2015	15
25751424	23411	Aguilar-Arnal L	NAD(+)-SIRT1 control of H3K4 trimethylation through circadian deacetylation of MLL1.	Nature structural and molecular biology	2015	17
23721554	23523	Kaneku H	De novo donor-specific HLA antibodies decrease patient and graft survival in liver transplant recipients.	American journal of transplantation 	2013	27
26604182	23523	Sawinski D	Successful Treatment of Hepatitis C in Renal Transplant Recipients With Direct-Acting Antiviral Agents.	American journal of transplantation 	2016	14
10858549	26291	Nishimura T	Identification of a novel FGF, FGF-21, preferentially expressed in the liver.	Biochimica et biophysica acta	2000	142
18252893	26291	Zhang X	Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans.	Diabetes	2008	164
19487637	26291	Chavez AO	Circulating fibroblast growth factor-21 is elevated in impaired glucose tolerance and type 2 diabetes and correlates with muscle and hepatic insulin resistance.	Diabetes care	2009	63
19702724	26291	Mraz M	Serum concentrations and tissue expression of a novel endocrine regulator fibroblast growth factor-21 in patients with type 2 diabetes and obesity.	Clinical endocrinology	2009	58
20451522	26291	Dushay J	Increased fibroblast growth factor 21 in obesity and nonalcoholic fatty liver disease.	Gastroenterology	2010	102
20675007	26291	Li H	Fibroblast growth factor 21 levels are increased in nonalcoholic fatty liver disease patients and are correlated with hepatic triglyceride.	Journal of hepatology	2010	66
20730630	26291	Itoh N	Hormone-like (endocrine) Fgfs: their evolutionary history and roles in development, metabolism, and disease.	Cell and tissue research	2010	46
22233381	26291	De Sousa-Coelho AL	Activating transcription factor 4-dependent induction of FGF21 during amino acid deprivation.	The Biochemical journal	2012	43
23217254	26291	Angelin B	Circulating fibroblast growth factors as metabolic regulators--a critical appraisal.	Cell metabolism	2012	52
24709036	26291	Gimeno RE	FGF21-based pharmacotherapy--potential utility for metabolic disorders.	Trends in endocrinology and metabolism	2014	35
25083607	26291	Fisher FM	Fibroblast growth factor 21 limits lipotoxicity by promoting hepatic fatty acid activation in mice on methionine and choline-deficient diets.	Gastroenterology	2014	29
25476453	26291	Owen BM	Tissue-specific actions of the metabolic hormones FGF15/19 and FGF21.	Trends in endocrinology and metabolism	2015	35
25577300	26291	Chen S	Resveratrol improves insulin resistance, glucose and lipid metabolism in patients with non-alcoholic fatty liver disease: a randomized controlled trial.	Digestive and liver disease 	2015	18
25685689	26291	Dushay JR	Fructose ingestion acutely stimulates circulating FGF21 levels in humans.	Molecular metabolism	2015	29
12883497	26503	Wai CT	A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C.	Hepatology	2003	518
14499785	26503	Harrison SA	The natural history of nonalcoholic fatty liver disease: a clinical histopathological study.	The American journal of gastroenterology	2003	85
15842581	26503	Huang MA	One-year intense nutritional counseling results in histological improvement in patients with non-alcoholic steatohepatitis: a pilot study.	The American journal of gastroenterology	2005	81
16729309	26503	Sterling RK	Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection.	Hepatology	2006	306
17393509	26503	Angulo P	The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD.	Hepatology	2007	235
18053320	26503	Klonoff DC	Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years.	Current medical research and opinion	2008	150
18291570	26503	Ozer J	The current state of serum biomarkers of hepatotoxicity.	Toxicology	2008	136
18390575	26503	Harrison SA	Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease.	Gut	2008	92
19013463	26503	Patton HM	Clinical correlates of histopathology in pediatric nonalcoholic steatohepatitis.	Gastroenterology	2008	50
19148800	26503	Hashimoto E	Hepatocellular carcinoma in patients with nonalcoholic steatohepatitis.	Journal of gastroenterology	2009	50
20664019	26503	Lazo M	Effect of a 12-month intensive lifestyle intervention on hepatic steatosis in adults with type 2 diabetes.	Diabetes care	2010	49
20801772	26503	McPherson S	Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease.	Gut	2010	78
20815808	26503	Gui J	Serum microRNA characterization identifies miR-885-5p as a potential marker for detecting liver pathologies.	Clinical science	2011	67
22006541	26503	Ratziu V	A phase 2, randomized, double-blind, placebo-controlled study of GS-9450 in subjects with nonalcoholic steatohepatitis.	Hepatology	2012	32
22271046	26503	Corpechot C	Noninvasive elastography-based assessment of liver fibrosis progression and prognosis in primary biliary cirrhosis.	Hepatology	2012	32
22828276	26503	Cox CL	Consumption of fructose- but not glucose-sweetened beverages for 10 weeks increases circulating concentrations of uric acid, retinol binding protein-4, and gamma-glutamyl transferase activity in overweight/obese humans.	Nutrition and metabolism	2012	30
22846613	26503	Bala S	Increased microRNA-155 expression in the serum and peripheral monocytes in chronic HCV infection.	Journal of translational medicine	2012	42
22993296	26503	Pollock NR	A paper-based multiplexed transaminase test for low-cost, point-of-care liver function testing.	Science translational medicine	2012	38
23316013	26503	Sieghart W	The ART of decision making: retreatment with transarterial chemoembolization in patients with hepatocellular carcinoma.	Hepatology	2013	37
23387384	26503	Musso G	Association of obstructive sleep apnoea with the presence and severity of non-alcoholic fatty liver disease. A systematic review and meta-analysis.	Obesity reviews 	2013	33
23396737	26503	Wong VW	Treatment of nonalcoholic steatohepatitis with probiotics. A proof-of-concept study.	Annals of hepatology	2013	39
23485521	26503	Bernstein DL	Cholesteryl ester storage disease: review of the findings in 135 reported patients with an underdiagnosed disease.	Journal of hepatology	2013	35
23928932	26503	Venkatesh SK	Magnetic resonance elastography for the detection and staging of liver fibrosis in chronic hepatitis B.	European radiology	2014	30
23980084	26503	Johnson PJ	Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study.	Journal of clinical oncology 	2013	96
24436062	26503	Konerman MA	Fibrosis progression in human immunodeficiency virus/hepatitis C virus coinfected adults: prospective analysis of 435 liver biopsy pairs.	Hepatology	2014	21
25099546	26503	Chung M	Fructose, high-fructose corn syrup, sucrose, and nonalcoholic fatty liver disease or indexes of liver health: a systematic review and meta-analysis.	The American journal of clinical nutrition	2014	23
25645567	26503	Blonde L	Association among weight change, glycemic control, and markers of cardiovascular risk with exenatide once weekly: a pooled analysis of patients with type 2 diabetes.	Cardiovascular diabetology	2015	16
23474284	56938	Moreau R	Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis.	Gastroenterology	2013	141
24950482	56938	Jalan R	Development and validation of a prognostic score to predict mortality in patients with acute-on-chronic liver failure.	Journal of hepatology	2014	33
11034317	57817	Krause A	LEAP-1, a novel highly disulfide-bonded human peptide, exhibits antimicrobial activity.	FEBS letters	2000	194
11113131	57817	Park CH	Hepcidin, a urinary antimicrobial peptide synthesized in the liver.	The Journal of biological chemistry	2001	329
12370282	57817	Nicolas G	The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation.	The Journal of clinical investigation	2002	302
17475779	57817	De Domenico I	The molecular mechanism of hepcidin-mediated ferroportin down-regulation.	Molecular biology of the cell	2007	108
18166790	57817	Kemna EH	Hepcidin: from discovery to differential diagnosis.	Haematologica	2008	51
19293425	57817	Theurl I	Regulation of iron homeostasis in anemia of chronic disease and iron deficiency anemia: diagnostic and therapeutic implications.	Blood	2009	74
21099112	57817	Gardenghi S	Hepcidin as a therapeutic tool to limit iron overload and improve anemia in β-thalassemic mice.	The Journal of clinical investigation	2010	65
21572427	57817	Portugal S	Host-mediated regulation of superinfection in malaria.	Nature medicine	2011	85
22306005	57817	Ganz T	Hepcidin and iron homeostasis.	Biochimica et biophysica acta	2012	145
22441209	57817	Ganz T	Macrophages and systemic iron homeostasis.	Journal of innate immunity	2012	47
22703180	57817	Pantopoulos K	Mechanisms of mammalian iron homeostasis.	Biochemistry	2012	64
23139325	57817	Drakesmith H	Hepcidin and the iron-infection axis.	Science	2012	119
24910614	57817	Spottiswoode N	Iron, anemia and hepcidin in malaria.	Frontiers in pharmacology	2014	21
11826411	64092	Chitturi S	NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome.	Hepatology	2002	155
15940625	64092	Ratziu V	Sampling variability of liver biopsy in nonalcoholic fatty liver disease.	Gastroenterology	2005	272
18956295	64092	Wieckowska A	Diagnosis of nonalcoholic fatty liver disease: invasive versus noninvasive.	Seminars in liver disease	2008	55
21497748	64092	Starkel P	Animal models for the study of hepatic fibrosis.	Best practice and research. Clinical gastroenterology	2011	38
23665288	64092	Pais R	A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver.	Journal of hepatology	2013	57
24042449	64092	Loomba R	The global NAFLD epidemic.	Nature reviews. Gastroenterology and hepatology	2013	164
26138654	64092	Ferslew BC	Altered Bile Acid Metabolome in Patients with Nonalcoholic Steatohepatitis.	Digestive diseases and sciences	2015	16
16150821	80339	Lake AC	Expression, regulation, and triglyceride hydrolase activity of Adiponutrin family members.	Journal of lipid research	2005	72
19224197	80339	Kotronen A	A common variant in PNPLA3, which encodes adiponutrin, is associated with liver fat content in humans.	Diabetologia	2009	69
19651814	80339	Kantartzis K	Dissociation between fatty liver and insulin resistance in humans carrying a variant of the patatin-like phospholipase 3 gene.	Diabetes	2009	71
19738004	80339	Sookoian S	A nonsynonymous gene variant in the adiponutrin gene is associated with nonalcoholic fatty liver disease severity.	Journal of lipid research	2009	76
19844213	80339	Romeo S	Morbid obesity exposes the association between PNPLA3 I148M (rs738409) and indices of hepatic injury in individuals of European descent.	International journal of obesity	2010	55
20034933	80339	He S	A sequence variation (I148M) in PNPLA3 associated with nonalcoholic fatty liver disease disrupts triglyceride hydrolysis.	The Journal of biological chemistry	2010	130
20373368	80339	Valenti L	Homozygosity for the patatin-like phospholipase-3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease.	Hepatology	2010	107
20648474	80339	Valenti L	I148M patatin-like phospholipase domain-containing 3 gene variant and severity of pediatric nonalcoholic fatty liver disease.	Hepatology	2010	58
20803499	80339	Santoro N	A common variant in the patatin-like phospholipase 3 gene (PNPLA3) is associated with fatty liver disease in obese children and adolescents.	Hepatology	2010	48
21254164	80339	Stickel F	Genetic variation in the PNPLA3 gene is associated with alcoholic liver injury in caucasians.	Hepatology	2011	59
21319195	80339	Valenti L	Patatin-like phospholipase domain-containing 3 I148M polymorphism, steatosis, and liver damage in chronic hepatitis C.	Hepatology	2011	62
21381068	80339	Sookoian S	Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease.	Hepatology	2011	143
21488075	80339	Trépo E	Impact of patatin-like phospholipase-3 (rs738409 C&amp;gt;G) polymorphism on fibrosis progression and steatosis in chronic hepatitis C.	Hepatology	2011	51
21878620	80339	Huang Y	Expression and characterization of a PNPLA3 protein isoform (I148M) associated with nonalcoholic fatty liver disease.	The Journal of biological chemistry	2011	47
22560221	80339	Kumari M	Adiponutrin functions as a nutritionally regulated lysophosphatidic acid acyltransferase.	Cell metabolism	2012	68
22878467	80339	Pirazzi C	Patatin-like phospholipase domain-containing 3 (PNPLA3) I148M (rs738409) affects hepatic VLDL secretion in humans and in vitro.	Journal of hepatology	2012	38
22952180	80339	Sevastianova K	Effect of short-term carbohydrate overfeeding and long-term weight loss on liver fat in overweight humans.	The American journal of clinical nutrition	2012	36
24114809	80339	Trépo E	Association between the PNPLA3 (rs738409 C&amp;gt;G) variant and hepatocellular carcinoma: Evidence from a meta-analysis of individual participant data.	Hepatology	2014	40
24445574	80339	Singal AG	The effect of PNPLA3 on fibrosis progression and development of hepatocellular carcinoma: a meta-analysis.	The American journal of gastroenterology	2014	40
24607626	80339	Liu YL	Carriage of the PNPLA3 rs738409 C &amp;gt;G polymorphism confers an increased risk of non-alcoholic fatty liver disease associated hepatocellular carcinoma.	Journal of hepatology	2014	39
24731669	80339	Yki-Järvinen H	Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome.	The lancet. Diabetes and endocrinology	2014	67
14647275	148738	Papanikolaou G	Mutations in HFE2 cause iron overload in chromosome 1q-linked juvenile hemochromatosis.	Nature genetics	2004	198
15998830	148738	Lin L	Competitive regulation of hepcidin mRNA by soluble and cell-associated hemojuvelin.	Blood	2005	88
16075058	148738	Niederkofler V	Hemojuvelin is essential for dietary iron sensing, and its mutation leads to severe iron overload.	The Journal of clinical investigation	2005	116
17540841	148738	Lin L	Iron transferrin regulates hepcidin synthesis in primary hepatocyte culture through hemojuvelin and BMP2/4.	Blood	2007	76
17938254	148738	Silvestri L	Furin-mediated release of soluble hemojuvelin: a new link between hypoxia and iron homeostasis.	Blood	2008	74
18326817	148738	Xia Y	Hemojuvelin regulates hepcidin expression via a selective subset of BMP ligands and receptors independently of neogenin.	Blood	2008	77
20542038	148738	Pietrangelo A	Hereditary hemochromatosis: pathogenesis, diagnosis, and treatment.	Gastroenterology	2010	82
16400329	151306	Watanabe M	Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation.	Nature	2006	377
19346331	151306	Hylemon PB	Bile acids as regulatory molecules.	Journal of lipid research	2009	149
24411485	151306	Duboc H	The bile acid TGR5 membrane receptor: from basic research to clinical application.	Digestive and liver disease 	2014	28
25584736	151306	Li T	Bile acids as metabolic regulators.	Current opinion in gastroenterology	2015	21
12730697	255738	Abifadel M	Mutations in PCSK9 cause autosomal dominant hypercholesterolemia.	Nature genetics	2003	363
15178557	255738	Dubuc G	Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia.	Arteriosclerosis, thrombosis, and vascular biology	2004	116
16465619	255738	Kotowski IK	A spectrum of PCSK9 alleles contributes to plasma levels of low-density lipoprotein cholesterol.	American journal of human genetics	2006	137
17452316	255738	Zhang DW	Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation.	The Journal of biological chemistry	2007	136
17461796	255738	Nassoury N	The cellular trafficking of the secretory proprotein convertase PCSK9 and its dependence on the LDLR.	Traffic	2007	66
18033751	255738	Careskey HE	Atorvastatin increases human serum levels of proprotein convertase subtilisin/kexin type 9.	Journal of lipid research	2008	60
18250299	255738	Kwon HJ	Molecular basis for LDL receptor recognition by PCSK9.	Proceedings of the National Academy of Sciences of the United States of America	2008	79
18343183	255738	Seidah NG	The activation and physiological functions of the proprotein convertases.	The international journal of biochemistry and cell biology	2008	96
22633824	255738	Stein EA	Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial.	Lancet	2012	88
23283366	255738	Al-Mashhadi RH	Familial hypercholesterolemia and atherosclerosis in cloned minipigs created by DNA transposition of a human PCSK9 gain-of-function mutant.	Science translational medicine	2013	33
23400816	255738	Kosenko T	Low density lipoprotein binds to proprotein convertase subtilisin/kexin type-9 (PCSK9) in human plasma and inhibits PCSK9-mediated low density lipoprotein receptor degradation.	The Journal of biological chemistry	2013	39
24625727	255738	Seidah NG	PCSK9: a key modulator of cardiovascular health.	Circulation research	2014	53
25778403	255738	Romagnuolo R	Lipoprotein(a) catabolism is regulated by proprotein convertase subtilisin/kexin type 9 through the low density lipoprotein receptor.	The Journal of biological chemistry	2015	27
26099511	255738	Zhang XL	Safety and efficacy of anti-PCSK9 antibodies: a meta-analysis of 25 randomized, controlled trials.	BMC medicine	2015	25
20389235	282617	Rallón NI	Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in HIV/hepatitis C virus-coinfected patients.	AIDS	2010	53
20434452	282617	Honda M	Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C.	Gastroenterology	2010	134
20621700	282617	Mangia A	An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response.	Gastroenterology	2010	85
20708617	282617	Fukuhara T	Variants in IL28B in liver recipients and donors correlate with response to peg-interferon and ribavirin therapy for recurrent hepatitis C.	Gastroenterology	2010	54
20931559	282617	Urban TJ	IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C.	Hepatology	2010	127
21111740	282617	Dill MT	Interferon-induced gene expression is a stronger predictor of treatment response than IL28B genotype in patients with hepatitis C.	Gastroenterology	2011	90
21146242	282617	Fabris C	IL-28B rs12979860 C/T allele distribution in patients with liver cirrhosis: role in the course of chronic viral hepatitis and the development of HCC.	Journal of hepatology	2011	50
21254179	282617	Charlton MR	Interleukin-28B polymorphisms are associated with histological recurrence and treatment response following liver transplantation in patients with hepatitis C virus infection.	Hepatology	2011	47
21468124	282617	Hofmann WP	A new standard of care for the treatment of chronic HCV infection.	Nature reviews. Gastroenterology and hepatology	2011	53
21480318	282617	Bitetto D	Complementary role of vitamin D deficiency and the interleukin-28B rs12979860 C/T polymorphism in predicting antiviral response in chronic hepatitis C.	Hepatology	2011	39
21931540	282617	Suppiah V	IL28B, HLA-C, and KIR variants additively predict response to therapy in chronic hepatitis C virus infection in a European Cohort: a cross-sectional study.	PLoS medicine	2011	41
21951981	282617	Asselah T	IL28B polymorphism is associated with treatment response in patients with genotype 4 chronic hepatitis C.	Journal of hepatology	2012	34
22180014	282617	Bochud PY	IL28B alleles associated with poor hepatitis C virus (HCV) clearance protect against inflammation and fibrosis in patients infected with non-1 HCV genotypes.	Hepatology	2012	38
22212565	282617	European Association of the Study of the Liver.	2011 European Association of the Study of the Liver hepatitis C virus clinical practice guidelines.	Liver international 	2012	35
22248663	282617	Thomas E	HCV infection induces a unique hepatic innate immune response associated with robust production of type III interferons.	Gastroenterology	2012	97
22351713	282617	Liu S	New protease inhibitors for the treatment of chronic hepatitis C: a cost-effectiveness analysis.	Annals of internal medicine	2012	48
22626609	282617	Poordad F	Factors that predict response of patients with hepatitis C virus infection to boceprevir.	Gastroenterology	2012	51
23703931	282617	Noureddin M	Association of IL28B genotype with fibrosis progression and clinical outcomes in patients with chronic hepatitis C: a longitudinal analysis.	Hepatology	2013	31
23836238	282617	Horner SM	Regulation of hepatic innate immunity by hepatitis C virus.	Nature medicine	2013	82
24184132	282617	Everson GT	Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infection.	Gastroenterology	2014	41
25048716	282617	Rehermann B	Immunological aspects of antiviral therapy of chronic hepatitis B virus and hepatitis C virus infections.	Hepatology	2015	26
25942723	282617	Poordad F	Fixed-dose combination therapy with daclatasvir, asunaprevir, and beclabuvir for noncirrhotic patients with HCV genotype 1 infection.	JAMA	2015	17
26476290	282617	Feld JJ	Sustained virologic response of 100% in HCV genotype 1b patients with cirrhosis receiving ombitasvir/paritaprevir/r and dasabuvir for 12weeks.	Journal of hepatology	2016	12
26547499	282617	Wilder JM	Safety and efficacy of ledipasvir-sofosbuvir in black patients with hepatitis C virus infection: A retrospective analysis of phase 3 data.	Hepatology	2016	10
26803446	282617	Abergel A	Ledipasvir-sofosbuvir in patients with hepatitis C virus genotype 5 infection: an open-label, multicentre, single-arm, phase 2 study.	The Lancet. Infectious diseases	2016	10
23291588	101180976	Prokunina-Olsson L	A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus.	Nature genetics	2013	201
25740255	101180976	Eslam M	Interferon-λ rs12979860 genotype and liver fibrosis in viral and non-viral chronic liver disease.	Nature communications	2015	29
